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ABSTRACT
Breast cancer is the most diagnosed cancer in women under 60 and the second most
diagnosed cancer in women over 60. While treatments for localized breast cancer are quite
successful with high survival rates at 99%, advanced breast cancer remains hard to treat with a
nearly 75% decrease in survival. Current treatments are inefficient at treating advanced stages of
breast cancer, and thus, new therapies are sorely needed to address the complexity of advanced
stage breast cancer. The ideal therapy would be capable of systemic administration, targets
cancer cells and spares normal tissue. Oncolytic adenovirus is an ideal therapeutic vector due to
its ease of manipulation, production and demonstrated clinical safety profile. In this study, we
engineered an oncolytic adenovirus to target the chemokine receptors CXCR4 and CXCR7. The
overexpression of CXCR4 and CXCR7 is implicated in the initiation, survival, progress and
metastasis of breast cancer. Both receptors bind to the ligand, CXCL12 (SDF-1), which has been
identified to play a crucial role in the metastasis of breast cancer cells. In this study we
incorporated a T4-fiber fibritin protein fused to CXCL12 into the knob domain of an adenovirus
to retarget the virus to the CXCR4 and CXCR7 receptors. We show that our modified virus
targets and infects CXCR4 and CXCR7 overexpressing breast cancer cells more efficiently than
a wild-type control. In addition, the substitution of the wild-type fiber and knob with our
modified fiber and knob did not interfere with oncolytic capability. Overall, the results of this
study set the foundation for future modifications or this vector and in vivo studies with the
CXCL12 modified virus within immunocompetent animal models.
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CHAPTER I. CURRENT BREAST CANCER TREATMENTS AND THE EVOLUTION
OF ONCOLYTIC VIROTHERAPY
1.1. Introduction
Breast cancer remains the most commonly diagnosed cancer in women aged 20-59 and
the second most commonly diagnosed cancer in women after age 60 in the United States and
makes up 30% of newly diagnosed cancer cases in women.1 It is estimated that about 268,600
women will be newly diagnosed with breast cancer in 2019.2 Approximately 3.8 million women
are living in the United States with a history of invasive breast cancer, including newly
diagnosed through long-term survivors without evidence of recurrence.2 Breast cancer diagnosis
prior to age 40 typically has poorer prognosis and higher mortality rates, likely due to these cases
presenting at later stages with more aggressive and larger tumors.3 It is estimated that more than
150,000 women are currently living with metastatic breast cancer in the United States.4
While great strides have been taken to identify high-risk patients, resulting in the
prevention of about 5%-10% of breast cancers based on screening for BRCA1 and BRCA2 gene
mutations, spontaneous development of breast cancer is less predictable.5 In fact, about 600,000800,000 women are diagnosed in the United States each year with benign breast lesions.6 Of
these women, those with proliferative growth, have an increased risk of developing breast cancer
by 2 to 5-fold.5 It is estimated that about 40,000-50,000 of these women with proliferative
growths will develop cancer. Unfortunately, preventative and treatment strategies are difficult to
utilize due to the inability to stratify the risk of precancerous lesions. With effective risk
stratification and treatment, about 20-25% of mortality from spontaneous breast cancer could
potentially be prevented.5
With advances in detection7 and treatments,1,8,9 breast cancer mortality has decreased
about 40% since 1989.10 In recent years, however, there has been a slight increase in incidence
1

rates, possibly attributable to the obesity epidemic.1 For local and regional breast cancer,
advances in technology and treatments have resulted in five-year survival rates of 99% and 85%,
respectively.1 For metastatic breast cancer, while survival rates have doubled from 18% to 36%
in women aged 15-49 since 1992,4 overall five-year survival for metastatic breast cancer is still
low at 27%.1 This is of great concern due to the 1 in 8 average chance of developing invasive
breast cancer.1,11 As a result, despite advances in the development of new therapies, breast cancer
is the second leading cause of women in the United States.1
1.2. Breast cancer categorization and treatment
Breast cancer typically presents as adenocarcinomas, or tumors of epithelial and
glandular origins, which make up about 95% of breast cancer cases.12 General classification
identifies tumors by origin, ductal, or lobular. In each case, the disease can be described as in situ
(contained within the ducts or lobes) or as invasive (penetration through the duct wall into the
surrounding tissue stroma). The most common type of breast cancer is invasive ductal carcinoma
(IDC). Typically, breast carcinomas are diagnosed as either IDC or ductal carcinoma in situ
(DCIS) due to the frequency of diagnosis.12 Other, rarer, types of breast cancers exist, but all are
primarily derived from epithelial and mesenchymal origins.
Regardless of histological presentation, breast cancer is staged based on progressive
evaluation using a modified form of the TNM Classification of Malignant Tumors (TNM)
system which first evaluates tumor size, lymph node evaluation, and metastatic disease status.13
Further staging for breast cancer then utilizes the Nottingham Grading System (NGS) to
determine tumor grade (degree of differentiation) and prognosis. After grading, hormone
receptor status is determined to identify the best course of treatment.

2

Breast cancer is categorized into two main molecular groups, hormone receptor-positive
(HR+)/human epidermal growth factor receptor 2 (HER2) positive and hormone receptornegative (HR-).14 These molecular groups are further broken down into five total subtypes; (1)
Luminal A, (2) Luminal B, (3) HER2 enriched, (4) basal (including triple-negative breast cancer
(TNBC)), and (5) normal-like tumors.11,15 Luminal A typically presents as HR+/HER2- and is
the most commonly diagnosed subtype. The second most commonly diagnosed subtype is TNBC
(HR-/HER2-) or basal-like. The less common subtypes are Luminal B (HR+/HER2±), HER2
enriched (HR-/HER2+), and normal-like tumors.15 These subtypes are the most commonly used
determinants for establishing a treatment approach. Currently, treatments for breast cancer are
delivered locally or systemically, typically targeting HR+ (estrogen receptor and progesterone
receptor) and HER2+ cancers. While many treatment options are available to breast cancer
patients outside of clinical trials (Table 1.1), most are inefficient at treating TNBC or metastatic
disease.
Unfortunately, even with advances in targeted therapeutic approaches, TNBC and
metastatic disease remain challenging to treat. For example, TNBC, a highly aggressive form of
breast cancer, affects 39% of breast cancer cases in premenopausal African American women:
nearly twice the incidence of cases in Caucasian women.11,16 TNBC also carries a greater risk of
metastasis to the lungs and central nervous system, particularly to the brain.17,18 In a multivariate
analysis of 3,000 women with brain metastases, TNBC had a higher risk of metastasizing to the
brain when compared to HER2 positive breast cancer.19 The same study also found that TNBC
brain metastases cases were more likely to relapse and were associated with decreased survival.
The difficulty in treating TNBC and metastatic disease lies with the lack of efficient or targeted
treatments that address the heterogeneity, location, and aggressiveness of TNBC and metastatic
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breast cancer. To further compound the severity of highly aggressive forms of breast cancer,
there is an overall 1 in 8 probability of developing invasive breast cancer1 and the incurable
nature of metastatic disease, results in a great need to develop more effective therapies.
Table 1.1. Current treatments for breast cancer therapy

Source: https://www.cancer.org/cancer/breast-cancer/treatment.html
Breast cancer susceptibility to treatment is typically reliant on the stage of diagnosis and
histological examination of tumors. Additionally, the choice of treatment regimen plays a role in
the effectiveness of the therapy. Unfortunately, despite advanced treatment approaches such as
adjuvant treatments based on molecular subtype, it is estimated that approximately 30% of
patients treated locally and regionally will present with recurrence at follow-up.20 It is important
to note that this does not include breast cancer treated at advanced stages, in which it is
understood that only 27% of breast cancer patients survive the first five years post-treatment.1
Regardless, breast cancer susceptibility to treatment has been improved with advances in
4

neoadjuvant treatment choices. For example, studies have shown an increase from 6%-15% to
30% of pathologically complete responses using anthracycline-based treatments with the
addition of a taxane agent.21,22 Unfortunately, even with the appropriate use of treatment, some
cases of breast cancer will be unresponsive, which is also known as primary resistance to
therapy.
For responsive breast cancer, some tumor cells can remain unresponsive leading to tumor
cell survival and treatment-resistant recurrence at variable time points post-treatment. Time of
recurrence is often unpredictable; for example, ER+ breast cancers tend to have a higher relapse
risk between 5-25 years post-treatment.20 On the other hand, TNBC has a shorter relapse window
with more severe prognosis and decreased survival.23 TNBC relapse is also associated with the
inability to eradicate tumors during treatment, despite high susceptibility to anthracycline and
taxane chemotherapies.23 Unfortunately, regardless of breast cancer susceptibility to primary
treatment, other factors such as patient comorbidities and age, tumor size, and lymph node
involvement can impact patient response to treatment and thus recurrence.
1.3. Evolution of oncolytic virotherapy, a brief history
Oncolytic virotherapy has been an extensively researched therapeutic approach, starting
in the late 1800s with simple observations of short-lived remission of cancers accompanying
infectious disease. In one notable case, a 42-year old woman was observed to experience
regression of myelogenous leukemia following influenza infection.24 Interestingly, after infection
influenza, the patient’s leukocyte count dropped, and the symptoms lessened, suggesting an
immunotherapeutic effect resulting from the infection. Unfortunately, leukemia recurred within
six months, and the patient died soon after. In 1904, a woman was diagnosed with cancer of the
cervix and was soon after bitten by a dog. A rabies vaccine was administered, and physicians

5

observed the disappearance of her tumor.25 This case, along with other experimental vaccinations
in cervical cancer cases were reported to show tumor shrinkage in several patients, however, all
eventually relapsed and died.25
In the first half of the 1900s, several observations and experiments were conducted
utilizing virus in cases of leukemia. The chickenpox virus, varicella zoster virus, was observed to
cause short term remission in patients who contracted it after diagnosis.26,27 In 1949, a
parvovirus that causes feline panleukopenia was experimentally used to inoculate children
diagnosed with leukemia.26 Two children from this study went into remission for about a month
before relapsing and succumbing to the primary disease.26 During this time, several studies were
assessing the inhibition of transplantable mouse sarcomas with the Russian Far East encephalitis
virus, now known as a subtype of tick-borne encephalitis virus, a flavivirus. In these in vivo
studies, the virus reportedly destroyed five different transplantable sarcomas during the course of
infection.28,29
Oncolytic virotherapy research quickly progressed during the 1950s and 1960s. Spurring
the sudden surge of interest was a rumor of a patient being cured of her malignant melanoma by
a rabies vaccination series. This interest prompted a report by the physician, George Pack, to
clarify the incidence. His report stated that a woman with malignant melanoma was treated for a
dog bite three years after beginning surgical removal of malignant lesions. She had no more
incidences of lesions for five years following the rabies vaccination, then had several nodules
removed and had been lesion free for two additional years, at the time of the report.30 The same
report described an experimental group of patients that underwent a series of rabies vaccinations
in order to attempt to replicate the patient’s outcome. Only two patients saw improvement in
their primary disease, but overall, no significant results were found.30
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Nevertheless, oncolytic virotherapy research increased dramatically in the 1950s. In
1952, a study was published on the experimental use of several viruses, most notably the Egypt
101 virus, a flavivirus, in human patients. This virus had been shown to have a preferential
infection in tumors resulting in tumor regression of a few patients.31 While exciting, the results
were only transient, with the authors identifying obstructions such as patient resistance to
multiple infections, the need for complete tumor eradication and the need for greater tumor
targeting and virus efficacy.31 In 1956, a study examined the effects of wildtype adenovirus as a
therapy for cancer. In patients with cervical cancer, the study found that 65% of patients had a
preferential infection of the primary tumor, as evidenced by tumor necrosis and viral presence.32
However, while evidence of virus infection in the tumor was seen, overall, there were not any
appreciable effects on the tumors or the patients.32 Later, in 1964, in an in vivo study using
guinea pigs with HeLa tumors, poliovirus type III was used to assess its oncolytic effects.33 The
poliovirus caused the HeLa tumors to become increasingly necrotic and mostly destroyed the
tumor, prolonging survival of the guinea pig host.33 While results as seen in this study, were
promising, the inability to identify a virus capable of completely destroying a tumor significantly
inhibited the use of viruses in the clinic.
Nearly a decade later in 1974, a landmark study was published in Japan on the practical
application of mumps virus in human cancer patients. This study reported on the local,
intratumor and intravenous administration of the mumps virus in a variety of cancer types, for
example, uterine cancer, stomach cancer, breast cancer, and malignant lymphoma. Of the ten
cases reported, all responded to therapy favorably, showing reductions in tumor size and
lessening of cancer-related symptoms such as pain, swelling, and nausea.34 Remarkably, several
patients had stable or regressed disease more than three years after treatment at the time of the
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report.34 This response was hypothesized as a possible anti-tumor effect mediated by the
reticuloendothelial system.34 This study was a turning point as it was one of the most successful
demonstrations of the oncolytic effects and anti-tumor stimulation of an oncolytic virus in
humans. Unfortunately, further studies exploring the mumps virus were not as successful, and
ultimately, a substantial decline in oncolytic virotherapy research followed in the 1970s and
1980s.
It was not until the early 1990s when advances in genetic engineering allowed for viral
manipulation to enhance viral specificity in cancer treatment. In 1991, the first reported
engineered oncolytic virus, a herpes simplex virus (HSV), had been genetically mutated to
attenuate neurovirulence by removing the thymidine kinase activity which inhibited viral
replication in non-dividing cells.35 This virus, dlsptk, effectively killed human glioma cell lines
in vitro and prolonged the survival of mice expressing human glioma tumors.35 This observation
was the first report of a virus engineered to enhance the specificity of an oncolytic virus and thus
began the era of engineering viruses for cancer therapy.
The approaches to engineering viruses for cancer therapy have been broken down into
categories: specificity, potency, delivery, and host immune interactions. The first move into
oncolytic virotherapy revolved around limiting replication to cancer cells and reducing off-target
toxicity. The aforementioned engineered HSV falls under the specificity category, as the virus
was attenuated for replication in dividing cells only.35 This can be further manipulated, as was
seen in a later version, an HSV containing an albumin promoter in the thymidine kinase gene
that further specified infection to albumin expressing hepatic cancer cells through the action of
transcriptional targeting.36 Overall, similar methods were seen in a variety of different viral
vectors during the 1990s as the field of oncolytic virotherapy explored potential therapeutic
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vectors. However, due to the significant increase in cancer-combating viral vectors during this
time, the remainder of this chapter will focus on the evolution of adenovirus as an oncolytic
vector.
1.4. Adenovirus as an oncolytic viral vector
Adenovirus (Ad) was initially described in the 1950s in which it was isolated from
adenoids in patients with respiratory infections.37,38 Adenovirus is characterized as a doublestranded DNA virus with a non-enveloped icosahedral capsid. Ranging from 70-100 nm, it
contains a linear genome of approximately 36 kb in size. The adenovirus capsid is made up of
three main proteins; hexon, penton, and fiber.39 While different serotypes may utilize alternate
receptors, the most common entry receptor for adenovirus is the Coxsackie and Adenovirus
receptor (CXADR; previously known as hCAR).40-42 Entry into the cell is primarily mediated by
the terminal domain of the fiber, known as the knob. After binding to CXADR, the capsid
undergoes conformational changes allowing binding to cellular integrins, which prompts
endocytosis into the cell. The resulting reduced pH in the endosome breaks down the fiber
structures and allows the penton base to interact with the endosomal membrane, causing it to
break down, with the release of the viral capsid into the cytoplasm. Microtubules interact with
the viral capsid, transporting it to nuclear pores where the viral DNA is released to enter the
nucleus, thus allowing replication to begin.43
The first clinical report on adenovirus, in 1956, utilized it as an anti-cancer agent sought
to treat cervical cancer in human subjects.32 While oncolytic activity was observed in patients’
primary tumors, metastases remained unaffected, regardless of the administration route.32 For the
next few decades, interest in adenovirus as an oncolytic vector ebbed until the rise of genetic
engineering. In the mid-1990s, recombinant adenovirus vectors began to emerge, as genetic
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engineering allowed for the attenuation of virulence, insertion of transgenes and refined
specificity and treatment potency. In 1993, one of the first reports of a recombinant adenovirus
utilized in cancer was of one that expressed the wild-type human p53 gene under the
cytomegalovirus (CMV) promoter.44 This vector resulted in a decrease in cell proliferation of the
SKOV-3 human ovarian cancer cell line. The authors suggested that this vector was a suitable
candidate to be continued into in vivo tumor models.44 Similarly, another recombinant
adenovirus was engineered to express the HSV thymidine kinase (TK) gene under the Rous
Sarcoma Virus (RSV) long terminal repeat promoter in a glioma mouse model.45 This research
was an effort to increase the potency of transgene delivery since the previously used retroviral
vector with the HSV-TK insert exhibited low transduction efficiency.45
In the following years, the number of recombinant adenoviruses for cancer therapy began
to increase rapidly. Notably, several generations of replication-deficient recombinant adenoviral
vectors were established. The first generation of recombinant adenoviruses contained E1 and E3
deletions, rendering them replication deficient. These deletions also allowed for larger transgene
insertions and were typically controlled by a chosen promoter sequence, e.g., the CMV promoter.
However, this generation lacked the capability of prolonged transgene expression and remained
highly immunogenic,46 prompting the engineering of the subsequent second generation of
recombinant adenoviruses containing additional mutations in the E2 and E4 regions. These
additional deletions allowed for increased transgene size and decreased immunogenicity;
however, transgene expression was not enhanced.47 These problems with transgene persistence
in vivo were hypothesized to be involved with the E4 deletion, This observation may, however,
be highly dependent on the choice of the promoter.48 Both generations at this point induced
innate and adaptive immune responses resulting in rapid vector clearance, affecting vector
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efficiency and transgene expression.49 Eventually, a third generation of replication-deficient
recombinant adenoviruses was produced that were completely stripped of viral protein genes
except for the end terminal repeats and the packaging sequences.50 These modifications resulted
in the adenovirus serving as a gene delivery system where transgene expression could be
prolonged without causing significant cytotoxicity or immunological responses.
During the development of replication-deficient Ad vectors, it was proposed that
conditionally-replicating adenoviruses could provide greater potency by exploiting the
adenovirus natural lytic replication cycle.51 This hypothesis was based on earlier studies in the
1950s conducted in cervical cancer patients with wild-type adenovirus inoculations.32 After this,
one of the first oncolytic adenovirus vectors was developed with the E1A promoter under the
transcriptional regulation of a prostate-specific enhancer (PSE).52 This transcriptionallyrestricted adenovirus was only able to replicate within prostate-specific antigen (PSA) producing
cells, for example, a PSA-producing prostate cancer cell line when compared to a non-PSAproducing prostate cancer cell line.52 By 1999, several oncolytic adenoviruses had been
developed to target melanoma,53 cervical cancer,53-55 carcinoma of the larynx,54
hepatocarcinoma,55 colorectal,55,56 ovarian,55 and bladder cancers.55 This research quickly led to
the first clinical trials using the oncolytic adenovirus vector, ONYX-015.
ONYX-015 was a replication-competent adenovirus vector containing a 55 kD deletion
in the E1B gene that restricted replication to cells with mutant or non-functional p53 protein.57 It
is well documented that most cancers heterogeneously exhibit p53 loss of function,58-60 and as a
result, this has been targeted through various gene therapy approaches. ONYX-015 quickly rose
to prominence with successful preclinical studies in ovarian,61 laryngeal,54 cervical,54,62 and
colon62,63 cancers. In clinical studies, ONYX-015 continued to demonstrate its safety and
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efficacy.64-68 During this time, another adenoviral vector, a replication-deficient adenovirus
expressing ornithine transcarbamylase (OTC) to treat OTC deficiency therapeutically,69 reached
clinical trials.70 While it was tolerated well by the majority of the participants one participant had
a fatal reaction.71 His death, resulting from a massive systemic immune response, was attributed
to a variety of overlooked factors during the clinical trial, including but not limited to: the
severity of his condition, being ineligible based on eligibility criteria and receiving the largest
dose.71,72 As a result, the fields of gene therapy and virotherapy were subjected to massive ethical
overhauls, stricter standards and IRB protocols, and an unavoidable loss of trust in the public
eye.72,73
1.5. Conclusion
Now, two decades later, virotherapy research has resulted in two approved viral vectors
for cancer therapy: one in China and the other in the United States. In 2003, China approved the
world’s first gene therapy product, a replication-deficient adenovirus expressing wild-type
human p53 for treatment of head and neck cancer.74 In 2015, Talimogene Laherparepvec (TVec), an oncolytic HSV-1 vector expressing human granulocyte-macrophage colony-stimulating
factor (GM-CSF) for the treatment of melanoma, was approved in the United States.75,76 During
this time, oncolytic virotherapy for breast cancer has been extensively researched with promising
results. The remainder of this dissertation will focus on oncolytic virotherapy for the treatment of
breast cancer, specifically utilizing adenovirus as a therapeutic vector.
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CHAPTER II. ONCOLYTIC VIROTHERAPY FOR BREAST CANCER TREATMENTa
2.1. Introduction: Advancing breast cancer treatment
Breast cancer continues to be the leading cause of death among women under 40 and the
second leading cause of death in those over 40.1 In 2017, newly diagnosed breast cancer cases
will make up nearly one-third of cancer diagnoses, with most of these cases being invasive.1,2
While early-stage breast cancer is treated with high success, advanced breast cancer remains
difficult to manage due to limitations of currently available treatments. Advanced breast cancer
tends to develop resistance to standard therapies, thus leaving palliative care as the remaining
option for these patients.
Current treatments for breast cancer fall under the cytotoxic, hormonal, and
immunotherapeutic categories, all of which have demonstrated limited efficacy in advanced
stages of breast cancer. With aggressive systemic therapies, patients often experience significant
toxicity, while still only achieving a 50% or lower response rate.3 These toxicities can persist as
long-term ailments, affecting the cardiac and neurological systems and overall quality of life, as
well as leading to the development of new primary cancers.4-9 Combination therapies have been
utilized to increase treatment efficiency, and are in extensive use today. However, tumors have
continued to develop resistance to these treatment combinations, leading to recurrence and
becoming more challenging to treat. Thus, new therapies are in high demand for the systemic
treatment of advanced breast cancer.
Research in oncolytic virotherapy has been ongoing for decades but only recently has the
approach advanced to investigations at the clinical level. In recent years, oncolytic viruses have
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been moving towards clinical application at an accelerated pace. One example is T-VEC, an
oncolytic herpes simplex virus (oHSV), which has been approved by the FDA for clinical use.10
Oncolytic viruses are particularly attractive due to the myriad of targeting strategies they can
utilize, thus extending them into the burgeoning field of personalized medicine. As a result,
many oncolytic viruses have been identified as potential new therapeutic agents for the treatment
of advanced breast cancer.
2.2.

Oncolytic viruses
Oncolytic viruses are derived or engineered from naturally occurring viruses to target and

kill cancer cells specifically. Currently, oncolytic viruses stem from most groups of viruses,
which are classified by their genome structure and modes of replication and transcription. These
viruses are subsequently engineered to utilize transcriptional and transductional targeting
strategies to restrict replication of oncolytic vector constructs to cancer cells, thus sparing normal
cells.
In breast cancer research, various viruses have already been extensively tested
preclinically to assess their oncolytic efficacy. Of the seven groups in the Baltimore
classification system, viruses from group I (double-stranded DNA viruses), group III (doublestranded RNA viruses), group IV (single-stranded RNA viruses – positive-sense), and group V
(single-stranded RNA viruses – negative-sense), have been extensively investigated as
candidates for breast cancer therapies, based on their previous use as vaccines or ease of
handling and genetic manipulation. As with current treatments in the clinic, oncolytic viruses
were initially being explored as single-agents and later in combination with existing therapies.
Here we discuss oncolytic viruses produced within the last decade that are being widely studied
for therapeutic application in breast cancer.
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2.3.

Group I viruses
Group I viruses are double-stranded DNA (dsDNA) viruses, which have been explored

for breast cancer therapy including oncolytic adenovirus (oAd), herpes simplex virus type 1
(HSV-1), and vaccinia virus (VV). Group I viruses require replication and transcription of their
DNA within the host cell nucleus yet does not integrate into the host DNA. Each virus utilized
for oncolytic therapy has its unique cell entry and replication patterns, which can be exploited
efficiently to deliver transgenes into the host cell nucleus.
2.3.1. Adenovirus
The human adenovirus (Ad) is the most studied oncolytic virus platform in breast cancer
research, as summarized in Table 2.1. Typically, Ad serotype 5 (Ad5) constructs target the cell
through the human Coxsackievirus and adenovirus receptor (hCAR) receptor found on most cell
surfaces. Subsequently, after binding to the receptor, the Ad undergoes endocytosis into the cell,
after which the virus genome is transported into the host cell nucleus where it is transcribed and
replicated for viral protein production and DNA packaging. Oncolytic Ads (oAds) have been
engineered to take advantage of this lifecycle with modifications to the physical characteristics
of the virion and the addition of targeting and therapeutic transgenes. One significant alteration
found in many oncolytic Ads is the use of tumor-specific promoters, which restrict replication to
cells expressing those genes. In addition, since breast cancer cells usually express low levels of
the hCAR receptor the Ad5 vector uses,11 modifications to the Ad fiber protein involved in
receptor binding have been shown to increase the infectivity of cancer cells.12,13
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Table 2.1. Summary of oncolytic Ad (Group I) viruses used in the context of breast cancer therapy.
Baltimore
Classification System

Virus

Vector

Modifications

Ad5/3mdr-∆24;
Ad5/3hTERT-∆gp; Ad5/3- E1 deletion; hTERT promoter
insertion; Ad3 fiber knob
cox2L∆24

Ad5/3-D24-GM-CSF

Double-stranded DNA
Viruses

Adenovirus

Refs.

Increase breast cancer
targeting

[14]

p16-Rb pathway defects,
tumor specific
immunotherapy

[15]

Insert HRE, ERE and E2F-1

Restrict to tumor cells

promoters; delete Ad E3

overexpressing estrogen

19K/6.7K genes; arm with
CD40L

receptor
and HIF-1α

Ad5-10miR145T

Insert 10 copies of miR145
down stream of E1A

Restrict replication to
cancer cells

[17]

Ad.sTβRFc; Ad.luc2

CMV promoter; Arm with
sTGFβRIIFc gene

Target TGF-β

[18]

mhTERTAd.sTβRFc

mhTERT promoter

Replication controlled

[19]

Ad.dcn

Express Decorin protein

mHAd.luc2

AdEHCD401

Group I

Express GM-CSF; 24 bp
deletion in E1A

Aim/Target

[16]

Produce functional
decorin in vivo; target
bone metastasis

[20]

Ad48 hypervariable region in
hexon gene

Reduce liver sequestering

[21]

AdLuc(HRG-fiber)

HRG ligand in HI loop of Ad
knob domain

Retarget to HER3

[22]

Ad5-pIX-RFP-FF-NK2

NK2 ligand in HI loop of Ad 5
knob domain

Retarget to cMet

[23]

AdKISS1

Arm with KISS1; Ad5/3
chimeric fiber

Increase infection in breast
cancer cells; tumor
suppressive

[25]

OAdmCherry

mCherry fused to pIX
protein; Ad5/3 chimeric

Oncolytic improvement
with temozolomide

[26]

(Ad)

fiber
CNHK600-IL24

Arm with IL-24

Induce apoptosis

[27]

P55-HTERT-HRETRAIL

Arm with TRAIL

Target TNBC

[28]

Increase cancer specificity;
SG500-dNK

Arm with DmDNK

combination with BVDU
or

[30]

dFdC
24 bp deletion in E1A;
Produce trastuzumab

Ad5/3-∆24-tras

Local antibody production
at tumor sites

[31]

Abbreviations: Ad: Adenovirus; BVDU: Bromovinyldeoxyuridine, CMV: Cytomegalovirus; dFdC:
Difluorodeoxycytidine; GM-CSF: Granulocyte-macrophage colony stimulating factor; HER3: Receptor
tyrosine-protein kinase erbB-3; HRG: Heregulin; IL-24: Interleukin-24; TGF-β: Transforming growth
factor beta; TNBC: Triple negative breast cancer; TRAIL: TNF-related apoptosis-inducing ligand
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In one study, tumor-specific promoters were utilized to increase breast cancer targeting.14 A
further modification was incorporated to display a chimeric Ad5 fiber protein that used the Ad
serotype 3 (Ad3) knob domain. The Ad5/3 modification allowed higher infection rates of breast
cancer stem cells in comparison to the wild-type Ad5 fiber.14 In a subsequent clinical study, the
same research team engineered an armed oAd using the Ad 5/3 platform. This virus, Ad5/3-D24GM-CSF, was restricted to tumor cells containing defects in the p16-Rb pathway through a 24
base pair deletion of the E1A promoter gene.15 Also, arming the virus with GranulocyteMacrophage-Colony-Stimulating Factor (GM-CSF) allowed for the tumor-specific lymphocyte
recruitment in human patients.15 Another research team constructed an oAd armed with a CD40
ligand (CD40L) transgene targeting breast cancer cells in vitro, in which early viral gene
expression was regulated by an Estrogen Response Element (ERE) and a Hypoxia Responsive
Element (HRE).16 Expression of the CD40L was shown to directly inhibit cancer cell growth by
binding to the surface receptor CD40. This oAd successfully inhibited breast cancer cell growth,
reduced tumor volumes, and displayed immune activation in vivo.16 More recently, a study
successfully targeted replication of Ad5-10miR145T to breast cancer cells through the insertion
of 10 copies of the binding site for tumor suppressor microRNA (miRNA) miR145 downstream
of Ad E1A gene.17 This particular targeting technique is relatively new and was shown recently
to suppress viral replication in cellular environments high in miR145.17 Due to decreased levels
of miR145 in cancer, Ad5-10miR145T was able to replicate in breast cancer cells resulting in
similar efficacy to the control virus.17
Many studies have been conducted with a focus on systemic delivery with efficient viral
targeting for the treatment of breast cancer metastasis. In a bone metastasis mouse model,
oncolytic Ad.sTβRFc was shown to inhibit bone metastasis and reduce tumor burden.18 This oAd
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was armed with a fusion protein, which targeted the transforming growth factor beta (TGF-β)
receptor 2 (TGFBR2). Expression of a soluble form of TGFBR2 fused with a human
immunoglobulin Fc fragment inhibited the TGF-β signaling pathway associated with breast
cancer bone metastasis.18 Further investigation of this virus and a similar oAd,
mhTERTAd.sTβRFc, which has its replication controlled by a modified human telomerase
reverse transcriptase (hTERT) promoter, were conducted using a well-established bone
metastasis mouse model.19 In this model, both viruses resulted in low liver toxicity and were
effective in inhibiting metastasis resulting in some cases to tumor-free mice.19 Another oAd,
Ad.dcn, was engineered to express decorin (dcn) protein, and also inhibited bone metastasis and
further prevented bone destruction by blocking the activity of TGF-β.20 To further address the
challenge of liver sequestering during systemic delivery, an oAd modified with a chimeric hexon
protein containing the Ad serotype 48 (Ad48) hypervariable region was tested in the same bone
metastasis model.21 This oAd showed an improved safety profile in comparison to its unmodified
counterpart with a reduction in liver uptake and damage.21
Low expression of the primary Ad receptor, hCAR, on breast cancer cells is often a
limiting factor for the efficacy of oAds. Due to the restricted expression of hCAR, infection is
poor, and alternative entry receptors have been explored to improve transductional targeting of
Ads. For example, AdLuc(HRG-fiber) containing the Heregulin (HRG) ligand in the HI loop of
the Ad knob domain successfully retargeted the virus to the receptor tyrosine-protein kinase
erbB-3 (HER3) in breast cancer cells.22 Another oAd, Ad5-pIX-RFP-FF/NK2, retargeted the
oAd to the tyrosine kinase receptor Met (cMet), which was found to be overexpressed in a
variety of cancers, including breast cancer.23,24 In addition, chimeric Ads using alternative
serotypes, such as the Ad3 fiber protein have been utilized to overcome reduced infection and

24

immune surveillance. This chimeric fiber platform, as mentioned above, utilizes the CD46
receptor, which is often upregulated in cancers. This platform was recently used in a study aimed
at improving infection in a breast cancer brain metastases cell line using an oAd armed with the
KiSS-1 metastasis suppressor protein (KISS1).25 AdKISS1 not only was able to infect the cell
line, but it also resulted in increased cytotoxicity, suppression of invasive properties, and
induction of apoptosis.25 In another study using the Ad5/3 platform, triple negative breast cancer
cells were targeted with OAdmCherry and the alkylating agent temozolomide.26 This
combination approach increased the efficacy of both treatments over mono-therapeutic controls
by significantly increasing autophagy and oncolytic cell death.26 These examples of oAds can
provide new platforms for additional modifications such as liver detargeting strategies and
therapeutic transgene expression for increased virus vector efficiency.
Further examples of modified oAds include those ‘armed’ with a therapeutically
expressing transgene that is produced alongside the oncolytic effects of the replicating Ad. One
research team created CNHK600-IL24, an oAd transcriptionally targeted by regulating Ad early
gene expression with an hTERT promoter and a promoter containing Hypoxia-Response
Elements (HREs). This construct was armed with an expression cassette in which the
Cytomegalovirus (CMV) promoter regulated expression of the apoptosis-inducing cytokine IL24.27 CNHK600-IL24 successfully inhibited breast cancer cell growth both in vitro and in vivo
and reduced metastasis after systemic injection.27 This research team also produced a similar
oAd, P55-HTERT-HRE-TRAIL, a virus armed with CMV-driven Tumor Necrosis FactorRelated Apoptosis-Inducing Ligand (TRAIL),28 which has been shown to induce apoptosis in
Triple-Negative Breast Cancers (TNBC) with a mesenchymal phenotype.29 TNBC was
successfully treated in both an orthotopic and a metastasis mouse model, resulting in tumor
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inhibition and significantly higher survival in the metastasis model when compared to a nonTRAIL expressing control vector.28 Another transcriptionally targeted oAd, SG500-dNK, armed
with the suicide gene deoxyribonuclease kinase (DmDNK) from Drosophila melanogaster, also
exhibited effective breast cancer targeting.30 However, this oAd was seen to exhibit some offtarget replication prompting the authors to recommend additional modification to restrict
replication to the targeted breast cancer cells further.30 Recently, another novel approach to
engineering an oAd has been demonstrated with the addition of current monoclonal antibody
immunotherapy trastuzumab. In a multiple targeting approach, Ad5/3-∆24-tras was both
transductionally and transcriptionally targeted, allowing for oAd-mediated breast cancer cell
lysis and production of the immunotherapeutic anti-HER2-mAb trastuzumab.31 The production
of trastuzumab de novo in addition to the oAd-mediated oncolysis caused growth inhibition,
tumor reduction and anti-tumor immune response.31
As oAds approach the clinic, the question arises of whether the best therapeutic use of
these oAds would be as a single therapy or as combination/adjuvant therapy. Given the lackluster
results in single therapy treatments for breast cancer, a combination approach would be better
suited to decrease the toxicity of treatments and increase their effectiveness. For example, the
previously described oAd, SG500-dNK, has also been paired with two common
chemotherapeutics to assess the effects that the oncolytic virus and chemotherapies have on each
other.30 The chemotherapeutic nucleoside analogs Bromovinyldeoxyuridine (BVDU) and
Difluorodeoxycytidine (dFdC) were used after the initial infection of TNBC cells in vitro. With
both analogs, synergistic effects were observed with an increase in cell killing while normal cells
were minimally affected.30 In an in vivo xenograft model using the TNBC cell line MDA-MB231, SG500-dNK in combination with dFdC resulted in a significant reduction in tumor growth
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and increased survival when compared with the oAd alone.30 To further illustrate combination
approaches, the Ad 5/3-D24-GM-CSF previously described,15 was tested in combination with the
chemotherapeutic drug Cyclophosphamide (CP).32 The MDA-MB-436 TNBC cell line was
treated in vitro and in vivo, resulting in increased cell killing and anti-tumor effects when Ad 5/3D24-GM-CSF was used in combination with CP.32 In human patients, this combination was
shown to be well tolerated without the occurrence of serious adverse events, and many patients
exhibited decreases in blood tumor markers.32 These studies highlight the potential of oAds in
the clinic and suggest more focus on the combined approaches may facilitate clinical
development and application in the near future.
2.3.2. Herpes Simplex Virus
Herpes Simplex Virus-1 (HSV-1) is a large, enveloped, dsDNA virus that fuses its
envelope to the host cells subsequently releasing its naked virion into the cell. Many of the
oncolytic HSV vectors incorporate mutations in viral genes or introduce additional therapeutic or
targeting approaches (Table 2.2). To restrict HSV-1 replication to cancer cells, the γ134.5 gene
was deleted, resulting in a transcriptionally targeted vector unable to replicate in neurons.33
Additional modifications to the entry mediator glycoprotein gD found on the HSV-1 envelope
allowed for retargeting to specific overexpressed receptors in breast cancer, such as the Human
Epidermal Growth Factor Receptor 2 (HER-2). This approach was utilized in the oHSV
construct R-LM249, which contained the anti-HER-2 single chain antibody trastuzumab in the
gD domain.34 This oHSV was successfully retargeted to the HER-2 receptor in breast cancer
cells,35 a receptor commonly overexpressed in some breast cancer subtypes.36 In addition,
treatment with R-LM249 in mice displayed no signs of toxicity, inhibited HER-2 positive tumor
growth and even resulted in tumor-free mice.35
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A separate oHSV, G47∆, contained several gene mutations to restrict replication to breast
cancer cells further. The additional mutations in the ICP6 and α47 genes restricted replication to
dividing cells37 and enhanced immune stimulation.38 In a study of pulmonary breast cancer
metastasis treatment with G47∆, the virus significantly reduced the number of tumors compared
to the control.39 In addition, G47∆ was successfully tested in a breast cancer stem cells both in
vitro and in vivo to assess its ability to target stem cells contributing to tumor growth.40 In
tamoxifen-resistant breast cancer cells and tumors, G47∆ was able to target, replicate in and
reduce tumor growth, demonstrating its potential as adjuvant therapy in the clinic.41 In an attempt
to negate the decreased virulence associated with the deletion of γ34.5 a recent study introduced
the C-terminus of murine protein phosphatase I regulatory subunit 15A (MyD116) to the Nterminus of the γ34.5 gene in a G47∆ recombinant (GD116).42 This insertion enhanced the
replication and cytotoxicity of GD116 in breast cancer cells in vitro, thus introducing a new
possible platform to develop oHSV with higher efficiency.42
Some oHSV are armed with cancer-combating proteins, enzymes, or drugs to achieve a
further therapeutic effect. In breast cancer treatment, the oHSV OSVP virus incorporated a 15hydroxyprostaglandin dehydrogenase gene encoding an enzyme that breaks down tumor
promoting prostaglandin E2.43 In mouse models of orthotopic and metastatic breast cancer, this
oHSV inhibited tumor growth, metastasis, and even contributed to immune stimulation after
treatment.43
In recent years, the oHSV HF10, a naturally mutated strain, was evaluated in human
breast cancer patients. In one study, breast cancer patients who had recurrences were treated with
single or recurrent doses of HF10 injected into single tumor nodules.44 Interestingly, these
patients demonstrated tumor size reductions and CD8-positive T cell infiltration that was
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suggestive of an antitumor response.44 A phase I dose escalation clinical trial was completed
using HF10, in which six with recurrent breast cancer of seventeen patients with advanced
cancers were included.45 While HF10 injections were safe and well-tolerated, a follow-up
clinical trial enrolling a larger cohort of breast cancer patients would likely yield more relevant
data to assess its efficacy as a therapy in this disease setting.
Several studies have evaluated oHSV efficacy in combination with other treatments such
as chemotherapies, immunotherapies, and targeted therapies. MGH2, a transcriptionally targeted
oHSV was assessed in conjunction with doxycycline-induced caspase 8 expression, recombinant
TRAIL, and/or chemotherapy paclitaxel.46 Treatment in vivo with doxycycline to induce caspase
8 expression resulted in apoptosis which increased MGH2 infection by facilitating virus spread
and therefore increased cell death intratumorally.46 Pretreatment with a paclitaxel-TRAIL
combination also increased MGH2 spread within tumors and contributed to higher cell death and
necrosis.46 Similarly, an Interleukin-12 (IL-12) expressing oHSV, M002 also exhibited increased
replication in breast cancer cells including in HSV-resistant cells when paired with select histone
deacetylase inhibitors.47 Another oHSV, HSV1-hGM-CSF, has been constructed to
transcriptionally target breast cancer cells and produce human granulocyte-macrophage colonystimulating factor upon replication.48 HSV1-hGM-CSF treatment given as an adjuvant therapy
with chemotherapeutic agent doxorubicin was able to significantly reduce tumor volume in a
breast cancer mouse model when compared to either treatment alone.48 Similar effects were
shown with HF10 when combined with the monoclonal antibody bevacizumab in treatment
against a xenograft mouse model.49
Recently, a unique study was carried out combining the glioma-specific oHSV,
rQNestin34.5 with Chimeric Antigen Receptor (CAR) modified Natural Killer (NK) cells
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expressing an Epidermal Growth Factor Receptor (EGFR) antibody fusion (EGFR-CAR-NK92).50 This approach can target both EGFR expressing cancer cells and EGFR-negative cancer
cells within the tumor. Herein, Breast Cancer Brain Metastases (BCBM) were initially treated
intratumorally with the EGFR-CAR-NK-92 cells and subsequently treated with the oHSV.50
Similar to the studies previously described, the combination here reduced tumor growth more
than the single therapy controls and resulted in significantly increased survival in the mice.50
Overall, the trend observed with oAd experiments was replicated using oHSVs, suggesting that
combination approaches are superior to single therapy approaches. Due to the recent FDA
approval of Imlygic (talimogene laherparepvec or T-VEC) as an oHSV for clinical treatment of
melanoma,10 advancement of oHSV into the clinic for breast cancer treatment may not be far.
2.3.3. Vaccinia Virus
The Vaccinia Virus (VV) is unique among dsDNA viruses in that its replication occurs
entirely in the cytoplasm, and not the nuclease of the cell.51 This feature is touted as an additional
safety benefit for an oncolytic virus due to the genome integration risk being eliminated. In
addition, VV has a natural tropism to tumors, making it an ideal candidate as an oncolytic
virus.52 In breast cancer, and oncolytic VV (oVV) has been shown to have high tumor cell
infectivity, replicate well and cause tumor regression (Table 2.2).
One strain, GLV-1h68, an oVV containing three gene modifications for successful visual
and immunohistochemical tracking, was able to successfully replicate in and kill canine
mammary tumor cells both in vitro and in vivo within a nude mouse model.53 In human breast
cancer stem cells demonstrating increased resistance to chemotherapy and irradiation, GLV-1h68
was able to replicate more efficiently when compared to the non-stem cell type counterparts.54
When assessed in a xenograft mouse model using breast cancer stem cells, GLV-1h68 was also
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able to significantly inhibit tumor growth, making this a potential oncolytic virus to target hard to
kill cancer stem cell populations.54 In another study, an oVV named GLV-1h164, armed to
express the single-chain antibody GLAF-2 against Vascular Endothelial Growth Factor (VEGF)
was tested in triple negative breast cancer.55 GLV-1h164 significantly regressed xenografts of
triple negative breast cancer tumors when compared to the non-GLAF-2 expressing parent
virus.55 In addition, VEGF was successfully targeted, as was seen by the decrease in vascular
flow and the inhibition of tumor vasculature post-treatment.55
A few studies in recent years have combined oVV with anti-cancer agents to increase
vector potency in breast cancer. One study combined GLV-1h68 with (1S)-seco-CBI-DMAI-βD-galactoside 1, a prodrug activated by β-galactosidase which is expressed in the virus.56 This
study was the first attempt using this type of prodrug in vivo in a tumor-bearing model. Herein, a
human metastatic breast cancer cell line, GI-101A, was used to form xenograft tumors in nude
mice that were treated first with the oVV GLV-1h68 and subsequently with the prodrug.56 As a
result, tumors were significantly reduced in volume compared with the controls, leading the
research team to surmise the potential of prodrug combinations with oVV.56 In another study,
also using a transcriptionally targeted strain, Vvdd, tested the virus in combination with a 4-1BB
(CD137) receptor antagonist.57 Vvdd contains additional deletions that further restrict replication
and cytolytic activity to tumor cells, enhancing this oVV tumor targeting and cytotoxicity.58 The
combination of the 4-1BB antagonist and Vvdd was able to inhibit tumor growth and increase
survival in an immunocompetent mouse model, as well as impact metastatic tumors at other sites
of the body.57 Also, antitumor effects were seen as a reduction of breast cancer metastasis and
tumor infiltration by CD8+ T cells, NK cells, and myeloid cells, highlighting the potential use of
VV in immunotherapy.57 As this VV research in breast cancer treatment expands, more drug
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combinations and immunotherapeutic applications should be addressed. With more studies, oVV
may advance to clinical trials in the near future.
2.4. Group III viruses
The double-stranded RNA (dsRNA) class of viruses represents a diverse group of
pathogens that infect a broad range of host species, from bacteria and fungi to animals and
plants. Most of these viruses have icosahedral capsid structures and contain from one to a dozen
different RNA molecules, each coding for one or more viral proteins. Upon infection, the
genomic dsRNA is transcribed into mRNAs that will serve for both translation and replication.
2.4.1. Reovirus
Reovirus is a dsRNA virus whose exact lifecycle mechanism is still not fully understood.
However, reovirus has been accepted as generally nonpathogenic in humans,59 and consequently
have been exploited as oncolytic viruses (Table 2.3). Interestingly, Type 3 Dearing reovirus
strain is naturally oncolytic and preferentially infects tumor cells. The oncolytic effect of this
strain in breast cancer cells has been explored in several studies. One study tested a panel of
breast cancer cells and found that all were susceptible to reovirus infection regardless of
hormone receptor status, whereas normal breast epithelial cells were not.60 This broad infection
capacity has been attributed to an activated Ras pathway or mutated Ras protein in cancer cells.61
When tested in mice using core biopsies of a human breast cancer tumor, reovirus treatment
successfully caused tumor regression.62 This study also found that reovirus is a sufficient vector
to target breast cancer stem cells, as they also exhibit aberrant Ras activity.62 Because of
encouraging studies indicating the reovirus type 3 Dearing strain would make an ideal oncolytic
virus for the clinic, it quickly rose to clinical testing. In 2013, a dose-escalation phase I trial was
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Table 2.2. Summary of oncolytic HSV and VV (Group I) viruses used in the context of breast cancer
therapy.
Baltimore
Classification System

Virus

Vector

Modifications

Aim/Target

Refs.

R-LM249

γ134.5 gene deletion;
Trastuzumab scFV in gD
domain

Retarget to HER2
receptors

[34]

Restriction to breast cancer
cells; immune reaction
enhancement

[37-41]

G47∆

GD116

OSVP

Herpes
simplex
virus
(HSV)

Group I
Double-stranded DNA
Viruses

gene deletion; ICP6 gene
mutation; α47 gene mutation

C-terminus of MyD116 inserted
in place of the C-terminus of
γ34.5

Enhance replication and
cytotoxicity

15-hydroxy prostaglandin
dehydrogenase gene

Break down tumor
promoting prostaglandin
E2

[43]

[44, 45]

[42]

HF10

Naturally mutated strain

Cellular effects;
Combination effects
with Bevacizumab
targeting VEGF

MGH2

Transcriptionally targeted;
Express
GFP

Combination apoptosis
inducing with compounds;
Tumor penetration
improvement

[46]

M002

Express IL-12

Viral replication in
combination with HDAC
inhibitors

[47]

Transcriptionally targeted;
Produce GM-CSF

Combination with
doxorubicin; Target
cancer stem cells
and chemo resistant
cancer
cells

[48]

rQNestin34.5

ICP34.5 mutation under control
of the Nestin promoter

Combination with CAR
NK cells expressing antiEGFR;
Target breast cancer brain
metastasis

[50]

GLV-1h68

Natural tropism to cancer cells;
RUC-GFP gene; βgalactosidase gene;
βglucuronidase gene
insertions

Target mammary tumors;
Replication in cancer
cells;
Combination approach
using prodrugs

[53, 54,
56]

GLV-1h164

Armed with GLAF-2 antibody

Target VEGF

[55]

Vvdd

Deletions in TK and VGF genes
or Serpin-1 and Serpin-2
genes

HSV1-hGM-CSF

Vaccinia
virus (VV)

γ134.5

Replication restricted to
tumor cells; enhanced
cytotoxicity

[57, 58]

Abbreviations: EGFR: Epidermal growth factor receptor; GFP: Green fluorescent protein; GM-CSF:
Granulocyte-macrophage colony-stimulating factor; HDAC: Histone deacetylase; HER2: Human
epidermal growth factor receptor 2; IL-12: Interleukin-12; NK: Natural killer; TK: Thymidine kinase;
VEGF: Vascular endothelial growth factor; VGF: Vaccinia growth factor.
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published reporting on reovirus (Reolysin) used as a local injection at the tumor site.63 While
patients ranged in cancer type, three were metastatic breast cancer patients. Of these three, one
was determined to have stable disease after treatment, and the study concluded that treatment
with reovirus proved to be safe in various advanced stage cancers.63
Reovirus has also been tested in combination with docetaxel and gemcitabine to study the
possible enhancement of its oncolytic activity. In the phase I clinical trial, 25 oncology patients
were treated with docetaxel in combination with reovirus. Of these patients, one presented with
metastatic breast cancer, which was considered to have undergone a complete response to the
treatment.64 A phase I trial combining gemcitabine with reovirus showed some positive effects in
cancer patients, including one breast cancer patient. However, the results of this study were less
definitive, prompting a suggestion for further exploration on this particular combination.65
Given that these combinational studies had only two breast cancer patients enrolled,
further exploration in a breast cancer cohort would be more enlightening on the potential of
reovirus in combination with commonly used breast cancer treatments. Recently, a preclinical
study combined reovirus with an anti-PD-1 inhibitor to target breast cancer cells both in vitro
and in vivo with an immunocompetent mouse model.66 The authors demonstrated that reovirus
was capable of inducing an immune response and when combined with anti-PD-1 therapy, tumor
reduction, and immune response was so marked that 70% of mouse cohort was cured.66
Remarkably, this combination enabled a systemic protective anti-tumor response that inhibited
tumor growth during a tumor re-challenge, thus providing further evidence in support for using
of reovirus in clinical trials.66 However, while reovirus has quickly risen to clinical trials, further
exploration with a breast cancer cohort of patients should be conducted to determine its potential
as a breast cancer treatment.
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The remainder of this review will touch on two additional groups of viruses that have
been advanced in breast cancer research. These more recent studies involve virus platforms that
could be utilized in breast cancer therapy. While some of these examples have been used in
treating other tumor types, breast cancer could be similarly targeted.
Table 2.3. Summary of oncolytic Group III and Group IV viruses used in the context of breast cancer
therapy.
Baltimore
Classification System

Virus

Vector

Modifications

Aim/Target

Refs.

Group III
Double-stranded RNA
Virus

Reovirus

Type 3 Dearing strain

Naturally oncolytic

Targeting and
efficacy

[60, 6266]

CVA21

Wild-type Kuykendall
strain

Breast cancer
infection and
replication

[68]

B3 strain

miR-1 and miR-217
insertions in 3' UTR

TNBC

[69]

Polio/rhinovirus
recombinant

Efficacy and effects
in prostate and breast
cancer

[71]

Coxsackievirus
Group IV
Positive sense
Single-stranded RNA
Virus
Poliovirus

PVSRIPO

Abbreviations: TNBC: Triple-negative breast cancer; UTR: Untranslated region.

2.5. Group IV viruses
The positive-sense single-stranded RNA (+ssRNA) class of virus is unique in that the
genome can immediately produce proteins as positive sense ssRNA that function as mRNA
within the cytoplasm. Those explored for use in breast cancer treatment are picornaviruses within
the genus Enterovirus, also known as intestinal viruses. Here we discuss the coxsackievirus and
polioviruses that have been examined in breast cancer research (Table 2.3).
2.5.1. Coxsackievirus
The naturally occurring Coxsackievirus A21 (CVA21) strain, which is mildly pathogenic
to humans, enters the cell through receptor-mediated infection, particularly using a complex of
the intercellular adhesion molecule 1 (ICAM-1) Decay-Accelerating Factor (DAF). This receptor
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complex is found to be overexpressed in many cancers, including breast cancer.67 One study
using CVA21 successfully destroyed breast cancer cells in single monolayers and spheroid
cultures, as well as in vivo SCID mouse models of xenograft and orthotopic metastatic breast
cancer.68 Recently, the coxsackievirus B3 strain has been genetically modified to increase safety
by inserting transcriptionally regulated miRNA sequences.69 Here, triple negative breast cancer
was treated in vitro and in vivo with results indicating an increase in safety as tumor growth was
suppressed.69 The encouraging results from these studies introduce coxsackievirus strains to
oncolytic virotherapy for breast cancer and pave the way for further safety studies as a single
agent as well as in combination drug approaches.
2.5.2. Poliovirus
Recently, a study using poliovirus has explored the treatment of breast cancer xenograft
models. While poliovirus is associated with neurological pathogenesis resulting in the
debilitating polio disease, this study utilizes the live-attenuated polio vaccine with an additional
rhinovirus gene insert to further prevent replication in neural cells.70 In addition, poliovirus uses
the CD155 receptor for entry, which is found in nearly all cancers, making it an ideal candidate
for oncolytic therapy. Here, PVSRIPO was tested on breast cancer cells in vitro and in vivo
xenografts resulting in cell lysis and delayed tumor growth.71 Most interestingly, treatment with
PVSRIPO resulted in robust immune activation and neutrophil infiltration in tumors,
highlighting its potential as an immunotherapeutic vector.71
2.6. Group V viruses
There has been additional breast cancer research conducted with viruses from the
negative-sense single-stranded RNA (-ssRNA) group. The -ssRNA group encompasses viruses
that have frequently been used to treat a variety of different cancers. However, the application
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for breast cancer has just been recently explored in vitro and in vivo as shown in Table 2.4 and
includes Vesicular Stomatitis Virus (VSV), Measles Virus (MV), Maraba virus, and New Castle
Disease Virus (NDV).
2.6.1. Vesicular Stomatitis Virus
Vesicular stomatitis virus (VSV) is a relatively new virus in breast cancer virotherapy,
and initial studies reveal its oncolytic potential as well as challenges that will require more
engineering and testing. VSV is unable to replicate in normal human cells yet can replicate in
oncogenic human cells through the cellular mutations accumulated in cancer cells, possibly
through antiviral pathways. This unique characteristic, in addition to its low pathogenicity in
humans, provides a safety profile sought after in virotherapy. However, treatment approaches
have struggled to increase its efficacy to rival that of more commonly used oncolytic viruses. For
example, a study using the oncolytic VSV (oVSV) mutant rM51R-M was unable to completely
inhibit the progression of tumor growth in an in vivo breast cancer model, even in combination
with IL-12.72 Recently, a study using the mutant VSV∆51 tested the vector in combination with
Microtubule-Destabilizing Agents (MDAs) in an effort to increase the efficacy of the oVSV
vector.73 Here, VSV∆51-resistant 4T1 breast cancer cells were treated in vitro with MDAs,
followed by the virus resulting in synergistic effects on the viral spread and cell death, including
VSV∆51-resistant breast cancer cells.73 In vivo, the vector in combination with MDAs was able
to delay tumor progression and increase survival as well as trigger antitumor activity.73
Interestingly, a study that examined a combination of VSV and VV in various established
cancer cell lines showed that the VV significantly enhanced VSV replication.74 Administering
the viral combination in an aggressive 4T1 breast cancer model, corroborated the in vitro data
while simultaneously establishing the safety of the combination.74 This result was further
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Table 2.4. Summary of oncolytic Group V viruses used in the context of breast cancer therapy.
Baltimore
Classification System

Virus

Vesicular
Stomatitis
Virus
(VSV)

Group V
Negative-sense
Single-stranded RNA
Virus

Measles
Virus (MV)

Maraba
Virus

Vector

Modifications

Breast cancer cell infection and
cell death in combination with
IL12

Refs.

rM51R-M

Naturally oncolytic

VSV∆51

Naturally oncolytic;
Deletion in matrix
protein

VSV∆51; VVD-eGFP;
VV∆B18R-eGFP

Vaccinia virus B18R
gene deletion

B18R gene product contribute
to viral replication; synergistic
effect
of viral co-infection

VSV-p14

Armed with FAST
protein

Increase virus infection and
spread

MV-GFP

Green fluorescent protein
expression

Modes of infection using
dendritic cell carriers or MV
alone in cancer cells

[79]

rMV-SLAMblind

Mutated to be incapable
of binding CD150
receptor

Infection via PVRL4 receptor

[80]

MV-m-uPA;
MV-h-uPA

Retarget to uPAR

MV-un-muPA

Modified for murine and
human targeting;
Targeted
to human CD46 and
murine uPAR

Effects on tumor stroma and
tumor infection by oncolytic
MV

[83]

MV-lambda; MV-sNAP; MV-lambdaNAP

Express human lambda
Ig chain (and/or)
neutrophil activating
protein

Effects of combination
treatment with alisertib

[84]

Increase virus oncolysis;
Attenuate replication in normal
cells

[85-88]

Tumor selectivity

[89]

G protein mutation
(Q242R); M protein
mutation (L123W)

MG1

Lentogenic
LaSota strain
Newcastle
Disease
Virus
(NDV)

Aim/Target

None

Oncolytic strain
MTH-68

None

Efficacy in combination with
MDAs

Increased infection and
targeting through tumor stroma

Combination radiofrequency
hyperthermia treatment of a
breast cancer patient

[72]

[73]

[74]

[75]

[81,
82]

[90]

Abbreviations: FAST: Fusion-associated small transmembrane protein; IL-12: Interleukin-12; MDAs:
Microtubule-destabilizing agents; MV: Measles virus; PVRL4: Poliovirus receptor-related protein 4
Nectin-4; uPAR: Urokinase-type plasminogen activator receptor.
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supported by using a more extensive panel of cancers using ex vivo tumor tissue slices,
also finding significantly enhanced viral replication when compared to singularly infected
cultures.74 While breast cancer specimens were not included in this study, the virus combination
approach can be utilized with other established oncolytic viruses in breast cancer research, as
seen in (Table 2.4). Recently, a study using a VSV armed with a reovirus Fusion-Associated
Small Transmembrane protein (FAST) demonstrated successful decreases in tumor growth and
increased survival in a syngeneic murine breast cancer model.75 This study highlighted the ability
of the FAST protein (p14) to increase virus transmission and dissemination within the model as
well as the induction of an anti-tumor immune response.75 Overall, VSV is just beginning to
enter breast cancer research; its natural oncolytic activity makes it a candidate for breast cancer
research, particularly in an immunotherapeutic capacity.
2.6.2. Measles Virus
Oncolytic measles viruses (oMV) derived from the attenuated Edmonston-B (MV-Edm)
vaccine strain have been tested in clinical trials for various cancers, and in recent years, the
exploration into breast cancer applications has begun. MV utilizes the following receptors:
CD4676 ubiquitously expressed on all nucleated cells, SLAM (signaling lymphocytic activation
molecule)77 often overexpressed in cancer cells, and the Poliovirus Receptor-related 4 (PVRL4)
protein.78 Attenuated oMV has been utilized to specifically target cancer cells, by limiting their
replication to oncogenic cells. In a study using both MV-GFP virions and MV-GFP-infected
dendritic cells, breast cancer cells were successfully infected by both modes, and the virus was
able to eradicate the cancer cells.79 This result illustrated an important approach of oncolytic
virotherapy in the context of preexisting immunity. The data from this study suggests that carrier
cells (such as dendritic cells used in this study) are efficient in bypassing MV-neutralizing
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antibodies and successful in delivering the vector to breast cancer cells.79 These results were
further supported by a pleural effusion xenograft model where MV-GFP rapidly infected and
spread amongst tumors, including distant metastasis using either free-virions or carrier dendritic
cells.79 In another study a CD150 (SLAM) blind strain was created, rMV-SLAMblind, resulting
in infection of breast cancer cells via the Nectin cell adhesion molecule 4 Nectin 4 or PVRL4
receptor, which coincidently is also overexpressed in breast cancer cells.80 This virus improved
upon the vaccine derivative, MV-Edm, in enhancing oncolytic activity both in vitro and in vivo
in breast cancer cells.80 Furthermore, safety testing in Rhesus monkeys concluded that rMVSLAMblind did not demonstrate symptoms typically seen in a measles infection.80
A separate research team sought to retarget MV to the urokinase-type Plasminogen
Activator Receptor (uPAR) which is primarily expressed in cancer and is associated with tumor
progression and metastasis.81 This study utilized both syngeneic and xenograft breast cancer
mouse models to test species-specific versions of the uPAR-targeting oMV vectors (MV-m-uPA
and MV-h-uPA). Both viruses were cancer-specific and were shown to delay tumor progression
in both models and significantly increased survival in the human xenograft model.81 A
subsequent study with these viruses utilized uPAR overexpression in tumor stroma fibroblasts
and determined that the tumor stroma could be utilized to transfer the infection to tumor cells,
induce apoptosis, and significantly delay tumor progression.82 Further modification of an oMV to
dual target murine and human cells in a xenograft breast cancer mouse model resulted in
increased survival and decreases of tumor-associated fibroblasts and endothelial cells.83 These
studies illustrate a unique approach to breast cancer treatment by targeting both the tumor stroma
and tumor cells that can provide additional avenues for successful clinical treatment.
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As with many oncolytic viruses being explored in clinical trials, combination therapies
with MV are of particular interest due to the evidence that these approaches can increase the
efficacy of viral therapies. For example, several MVs (e.g., MV-GFP, MV-lambda, MV-s-NAP,
and MV-lambda-NAP) have recently been tested with alisertib. Alisertib (MLN8237) is an
Aurora A Kinase inhibitor whose activity is synergistic with viral replication. The combination
of the oMV vectors with alisertib significantly improved breast cancer cell eradication compared
to virus-only treatment, and in some cases resulted in complete eradication in vitro.84 When this
combination was repeated in vivo using MV-lambda-NAP, the survival of a xenograft metastasis
mouse model of breast cancer was significantly improved, and in some cases resulted in
complete regression.84 In the pleural effusion model previously described, a combination of
alisertib and MV-s-NAP also increased survival significantly compared to single-agent therapy.84
With the combination of drugs such as alisertib, the efficacy of MVs can be increased and
utilized in clinical trials, leading to better outcomes and possibly the advancement of the oMV
vector to clinical use.
2.6.3. Maraba Virus
The maraba virus, another relatively new member of oncolytic virotherapy vectors, has
made its way into breast cancer research. In a study discovering the virus as a VSV-related
rhabdovirus with potent oncolytic activity, a recombinant Maraba, MG1 was engineered to
increase its oncolytic potential while attenuating its ability to replicate in normal cells.85 Maraba
MG1 was safely administered intravenously, and repeated doses in a syngeneic colon cancer
model resulted in complete regression of tumors.85 In a subsequent investigating the 4T1 mouse
breast cancer metastasis model, administration of MG1 or a UV-inactivated version in a
preoperative treatment scheme dramatically reduced lung metastasis.86 Assessment of MG1 in
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combination with paclitaxel treatment further enhanced breast cancer cell killing by enhancing
viral replication both in vitro and in vivo.87 Even more remarkable, a recent study examined
long-term immune response effects to intratumorally injected MG1 when combined with surgical
resection post-treatment, showed that the virus was able to slow metastases and even resulted in
complete responses in a subset of in vivo breast cancer models examined.88 Through re-challenge
mouse models and gene expression analysis, the authors concluded that immune activation was
crucial to the overall response in vivo.88 Further illustrating this point, mouse cohorts that were
first treated in vivo with MG1, followed by surgical resection and anti-PD-1 therapy,
demonstrated 60-90% complete responses after tumor re-challenge.88 These recent results further
support previously described data points in other studies that show an increase in treatment
efficacy when oncolytic viruses are used in conjunction with other anti-cancer therapeutics.
2.6.4. Newcastle Disease Virus
The final vector of the -ssRNA group explored in breast cancer is Newcastle Disease
Virus (NDV). While NDV has been examined in the past as an oncolytic vector, only in recent
years has it been tested in breast cancer. A recent study, assessing the pro-inflammatory response
to NDV in a number of tumor lines, including breast cancer, found that NDV is a potent activator
of Type I and II interferon responses in addition to Interleukin 6 (IL-6) expression.89 The authors
of this study concluded that NDV has potential as an immunotherapeutic agent. More research is
needed to assess the NDV vector efficacy as an oncolytic virotherapy. However, it is worth
mentioning a successful case study using NDV in which a 70-year-old female with invasive
ductal breast cancer that had metastasized to the liver was treated with a combination of targeted
hyperthermia, Dendritic Cell (DC) immunotherapy, and NDV injections over the course of five
years after initial diagnosis.90 Since the patient opted out of conventional treatment (i.e.,

42

chemotherapy) and chose the personalized immunotherapy regimen, her case introduced data
from a previously untreated source. The patient tolerated the therapy well with no changes to
lifestyle or quality of life, as often seen in those undergoing conventional therapy. At the time of
its publication, the patient had surpassed the six-month expected survival by 60 months.90 In
addition, the metastasis had not progressed and remained stable throughout therapy.90 This
finding illustrates a compelling argument that chemotherapy is inadequate; instead, successfully
modulating breast cancer through oncolytic virotherapy and immunotherapy could provide a
long-term survival advantage to individuals over conventional treatment approaches.
2.7. Conclusions: A multi-combinational approach
Throughout the development of oncolytic virotherapy, a reoccurring theme that has been
gaining traction in the field, particularly in breast cancer, has been combinational approaches.
Monotherapeutic approaches have been crucial to understanding the mechanisms involved in
virus-specific contributions to therapeutic response and optimizing oncolytic activity. However,
the inadequate efficacy and lack of complete responses at the clinical level are driving new
combinational approaches. Anti-cancer drugs can often result in synergistic effects when
combined with oncolytic virotherapy, presenting a platform for personalized therapies. These
combinations have enhanced both the drug and viral vector efficacy in vitro and in vivo in most
cases provided a greater therapeutic effect. Importantly, the combinations discussed in this
review have shown to improve and support anti-cancer immune responses.
An innovative approach to oncolytic virotherapy therapy would be the combination of
different oncolytic viruses to target the same disease in distinct ways. The first approach of this
strategy was published in 2010 by a research team in Canada, combining VSV and VV. This
study examined the combination of various established cancer cell lines, which resulted in the
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finding that the VV significantly enhanced VSV replication.74 As described earlier, VSV is new
to breast cancer virotherapy and is still met with challenges affecting its overall efficacy.
However, this study introduced a new method that could enhance VSV replication
dramatically.74 Administering the treatment in the context of an aggressive 4T1 mouse tumor
model in vivo, corroberated the in vitro data as well as established its safety.74 Further infection
of ex vivo tumor tissue slices from a range of cancers supported the in vitro and in vivo data as
well, showing a significant enhancement of viral replication when compared to singularly
infected cultures.74 While breast cancer specimens were not included in this particular study, the
virus combination approach opens the door to exploit those more established oncolytic viruses in
breast cancer research.
Although oncolytic viruses for use in breast cancer treatments are taking great strides
towards the clinic, many hurdles remain. For example, Ad vectors have faced challenges in
clinical trials because of limited efficacy observed in patients to date. However recent studies
suggest that therapeutic benefits can be improved when Ads are used in combination with
therapeutic drugs26,30-32 or immune checkpoint inhibitors.91 This approach is a particularly
promising avenue as Ads have already been studied extensively for breast cancer treatment and
have an established safety profile in clinical trials. Likewise, HSV-based therapeutic vectors such
as T-VEC may be insensitive to treating all cancer cell types due to the deletion of the γ134.5
gene, which also compromises the replication of the virus.42 Novel improvements to the HSV
platform could be utilized to enhance the anti-tumor effects on breast cancer.42 VV vectors have
a number of advantages including selective and robust cancer cell killing using in vitro and invivo preclinical models of breast cancer.53-58 However, despite extensive safety experience as a
live vaccine, clinical trials using oVV vectors have not included breast cancer patients to date.
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Recently, newer vectors such as reovirus,66 MV,82,83 and Maraba virus88 have shown promising
preclinical results in the treatment of breast cancer. It is too soon to determine the clinical impact
of these virus platforms in a clinical setting, since they will likely need further vector
improvements and extensive preclinical testing.
Table 2.5. Clinical trials for breast cancer treatment using oncolytic virotherapy approaches.
Virus

Additional
Therapy

Disease

Status

ID

I

vvDD-CDSR (VV)

None

Melanoma, HNSCC, Breast, Liver,
colorectal, and Pancreatic cancers

Completed

NCT00574977

I

CVA21 (Coxsackievirus)

None

Solid tumor cancers

Completed

NCT00636558

I

HF10 (HSV)

None

Refractory HNSCC, Skin SCC,
Breast carcinoma, Melanoma

Completed

NCT01017185

II

Reolysin (reovirus)

Paclitaxel

Metastatic breast cancer

Completed

NCT01656538

I

MV-NIS (MV)

None

Metastatic breast cancer and
HNSCC

Active, not
recruiting

NCT01846091

I

VCN-01 (Ad)

Gemcitabine
Abraxane

Advanced/metastatic tumors
pancreatic adenocarcinoma

Recruiting

NCT02045602

I/II

MG1MA3 (oncolytic Maraba)
and AdMA3 (Ad vaccine)

None

Advanced/metastatic
solid tumors

Recruiting

NCT02285816

I

Toca 511 (retroviral
replicating vector)

Toca FC
(5fluorocytosine
formulation)

Solid tumors, Lymphoma

Recruiting

NCT02576665

I/II

JX-594 (VV)

Metronomic CP

Advanced breast cancer, softtissue sarcomas

Recruiting

NCT02630368

I/II

Talimogene Laherparepvec
(HSV)

Paclitaxel

TNBC

Recruiting

NCT02779855

I

Pexa-Vec (VV)

Ipilimumab

Metastatic/Advanced tumors

Recruiting

NCT02977156

TNBC and NSCLC

Recruiting

NCT03004183

Stage II-IV TNBC

Not yet
recruiting

NCT03564782

Phase

II

ADV/HSV-tk (Ad)

Valacyclovir,
Pembrolizumab,
and stereotactic
XRT

I

PVSRIPO (oncolytic
poliovirus)

None

Abbreviations: Ad: Adenovirus; CP: Cyclophosphamide; HNSCC: Squamous cell carcinoma of the head
and neck; HSV: Herpes simplex virus; MV: Measles virus; NSCLC: Nonsmall cell lung cancer; SCC:
Squamous cell carcinoma; TNBC: Triple-negative breast cancer; VV: Vaccinia virus; XRT: Radiation
therapy.
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As discussed throughout this review, combination approaches using current therapeutic
drugs promise an increase in therapeutic efficacy and highlighting how quickly the oncolytic
virotherapy field is developing in cancer research. Currently, there are a number of Phase I and II
clinical trials using oncolytic viruses that are completed or ongoing for treating breast cancer
patients, as shown in Table 2.5. The majority of these are utilizing a combinational approach to
treat advanced-stage cancers. However, while the combination approach appears promising,
further challenges lie in identifying and developing successful and safe combinations. Proper
combinations will likely rely on patient disease progression, prior chemotherapy and resistance,
the milieu of gene mutations in oncogenes and tumor suppressor genes, virus receptor
expression, and immune status. This approach will likely present a challenge in clinical trials as
it suggests a degree of personalization that may not be easily replicated among individuals.
Nevertheless, with safety profiles established for many of the vector platforms, oncolytic
virotherapy represents a new era of breast cancer therapy in which potentially effective and welltolerated regimens may also further improve quality of life post-treatment.
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CHAPTER III. CXCL12 RETARGETING OF AN ONCOLYTIC ADENOVIRUS
VECTOR TO CXCR4 AND CXCR7 RECEPTORS IN BREAST CANCER
3.1. Introduction
Breast cancer remains the most commonly diagnosed cancer in women under 60 and
second-most in women over 60 in the United States.1 While great progress has been made in
developing targeted therapies for breast cancer, advanced breast cancer continues to have high
mortality, with 5-year survival rates at 27%,1 thus highlighting the need for more efficient
therapies. Specifically, new therapies are needed that are capable of treating advanced and triple
negative breast cancer (TNBC). While a variety of targeted therapies are available for hormone
receptor-positive breast cancers, especially at earlier stages, standard therapies, such as
chemotherapy and radiation remain the only choices for TNBC. Therefore, a more efficient
therapy, capable of targeting breast cancer cells while sparing normal tissue, is sorely needed.
Adenoviruses have been investigated for as anti-cancer vectors for over 60 years due to
their natural ability to replicate in and lyse infected cells.2 Adenoviruses are ideal therapeutic
vectors due to being easy to manipulate, allowing for large transgene inserts and large-scale
production. In addition, adenovirus vectors have been demonstrated to be clinically safe for local
and systemic administration during oncolytic clinical trials.3,4 Several characteristics of
adenovirus vectors, however, such as cancer cell targeting, immune system evasion, and
intratumor spread, have limited their efficacy and have prevented their successful use in the
clinic.5 Fortunately, in recent years, oncolytic adenovirus vectors for breast cancer have
advanced to more sophisticated designs, incorporating tumor-specific promoters and transgene
inserts,6-10 fiber and capsid modifications and the development of hybrid constructs.11-16
Adenovirus vectors have been extensively explored in breast cancer treatment utilizing
various targeting approaches and induction of therapeutic transgenes. A predominant approach to
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engineering recombinant adenovirus vectors has been to target cancer cells efficiently. Due to the
downregulation of the Adenovirus 5 (Ad5) endogenous receptor, Coxsackie and Adenovirus
receptor (CXADR), there has been a drive to investigate alternative receptors for effective viral
entry.17 Several oncolytic vectors have been designed to target alternative entry pathways
through fiber and knob modifications. For example, replacing the Ad5 knob with the Ad3 knob
retargets an oncolytic adenovirus to the CD46 receptor 18 and has been utilized extensively to
target breast cancer cells.11,13-15,19 In addition, breast cancer cells overexpressing the receptors
HER3 and HER4 have been targeted with a fiber-modified oncolytic adenovirus utilizing the
epidermal growth factor-like domain of human heregulin-α (HRG) inserted into the HI loop of
the Ad5 fiber.12 In another study, insertion of RGD-4C into the HI loop also allowed retargeting
of an adenovirus to alpha-v-beta integrins in breast cancer cells.20 Also, an adenovirus modified
to incorporate a polylysine motif within the fiber retargeted the adenovirus to heparan sulfate
proteoglycans (HSPGs) in breast cancer cells in vitro and in vivo.21
One identified target is CXCR4, a 7-transmembrane chemokine receptor that is the most
commonly overexpressed chemokine receptor in cancer, including breast cancer.22 CXCR4
functions as a mobilizer for hematopoietic stem cells and naïve lymphocytes and plays critical
roles in the patterning of cell lineages during embryogenesis.23 Currently, the only known ligand
to CXCR4 is SDF-1, also known as CXCL12.24 In breast cancer, CXCR4 in tumor cells plays
roles in the initiation, growth, progression and ultimately, the migration of tumor cells25 and
metastasis at distant sites.26-28 In addition to CXCR4, another chemokine receptor, CXCR7, is
capable of binding/sequestering SDF-1.29 CXCR7 has been found to be directly overexpressed in
cancer cells,30 as well as in tumor-associated endothelial cells31 and macrophages.32 CXCR7 also
has been implicated to act during stages of tumor progression, e.g., tumor cell initiation, survival,
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progression, and metastasis.32-34 Overall, the distribution of both overexpressed receptors in
breast cancer cells and tumors has caused the receptors to become attractive targets for cancer
therapy.
Previously, we successfully retargeted a replication-deficient Ad5 to CXCR4overexpressing breast cancer cells via a bi-specific adaptor molecule, sCAR-CXCL12.35 The
sCAR-CXCL12 adapter resulted in efficient retargeting of the adenovirus to CXCR4overexpressing cancer cells. In addition, in a human ex vivo liver slice model, the virus
complexed with the adapter allowed for a reduction in liver tissue infection.35 Furthermore,
injection of adenovirus complexed with sCAR-CXCL12 into a SCID-bg mouse model further
demonstrated liver-off and tumor-on biodistribution.35 In the current study, we modified an
oncolytic adenovirus (Ad5) to express the human chemokine ligand CXCL12 as the targeting
moiety of an Ad5-T4 fibritin modified fiber. Herein, we sought to investigate the efficacy of
incorporating the CXCL12 ligand for increasing infection of breast cancer cells overexpressing
CXCR4 and CXCR7. We hypothesize that by incorporating the CXCL12 ligand as a
transduction-based modification, we will retarget the oncolytic adenovirus to the CXCR4 and
CXCR7 receptors and as a result increase the infection efficiency when compared to its wildtype counterpart. We found that our adenovirus with efficiently incorporated CXCL12 and
infected breast cancer cells that overexpress CXCR4 and CXCR7 receptors.
3.2. Materials and Methods
3.2.1. Cell lines and viruses
The F28 cell line was provided by David T. Curiel (Washington University School of
Medicine at St. Louis, St. Louis, MO) and maintained in DMEM supplemented with 10% FBS,
1% penicillin/streptomycin, 1% NEAA, and 400 ug/mL Zeocin. The human embryonic kidney
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cell line HEK293 and breast cancer cell lines MDA-MB-436 (TNBC/basal), MDA-MB-231
(TNBC/basal), ZR-75-1 (Luminal A), BT-20 (undefined), and MCF-7 (Luminal A) (ATCC,
Manassas, VA) were maintained in DMEM supplemented with 10% FBS (Gemini, West
Sacramento, CA), 1% penicillin/streptomycin (ThermoFisher, Waltham, MA) and 1% NEAA
(ThermoFisher). The human mammary gland epithelial cell line, MCF-12A, was maintained in
DMEM/F12 containing 5% donor horse serum, .5ug/mL hydrocortisone, .01 mg/mL bovine
insulin, 100 ng/mL cholera toxin and 20 ng/mL human EGF.
HEK293-CXCR4 was maintained in the same medium as the parental cell line with the
addition of 200 ug/mL G418 (HyClone, South Logan, UT). The Chinese Hamster ovary cell
lines, CHO 1 and CHO 1-hCAR, were kindly provided by Rhonda Cardin (Louisiana State
University School of Veterinary Medicine, Baton Rouge, LA) and maintained in RPMI 1640
(Genesee Scientific, San Diego, CA, USA) containing 10% FBS, 2mM L-glutamine, 1%
penicillin/streptomycin, 10 ug/mL thymidine (Sigma-Aldrich, St. Louis, MO, USA), 10 ug/mL
adenosine (Sigma-Aldrich) and 10 ug/mL 2-deoxyadenosine (Sigma-Aldrich). CHO 1-hCAR
was also supplemented with 100 ug/mL Zeocin (InvivoGen, San Diego, CA, USA). CHO 1CXCR4 and CHO 1-CXCR7 were maintained in the same medium as the parental CHO 1, with
the addition of 800 ug/mL G418. All cell lines were maintained at 37 ̊C in a humidified 5% CO2
atmosphere.
To produce our recombinant fiber-modified adenovirus we used an established
technique.36 Using this technique, a shuttle plasmid containing the red fluorescent protein
attached to the minor capsid protein IX was combined in and E. coli strain, BJ5183, which are
electrocompetent cells (Agilent Technologies, Santa Clara, CA) with an Ad5 viral backbone
plasmid containing the fiber-fibritin-CXCL12 insert. BJ5183 is an E. coli strain developed to
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efficiently recombine to plasmids to produce large adenovirus plasmids. After recombination,
Ad5-pIX-RFP-FF/CXCL12 (Ad5-ffCXCL12) was grown on 100 ug/mL Kanamycin agar plates
incubated overnight in 37 ̊ C for a maximum of 16 hours. After incubation, the smallest colonies
were chosen for amplification as these are most likely to contain recombinants. Colony
amplification was conducted in 5mL LB broth with 100 ug/mL Kanamycin, overnight in a
shaking incubator for a maximum of 16 hours. Following amplification, plasmids were extracted
via miniprep (Bio-Rad, Hercules, CA) and analyzed via HIND III restriction enzyme digestion
(NEB, Ipswich, MA) to screen for positive recombinants. Upon positive recombinant clone
verification, clones were then analyzed via PCR for the E1A, pIX, Ad5-E4, and Ad5-penton
genes.
A clone was chosen that was positive for all genes and subsequently transduced into
XL10-Gold ultracompetent E. coli cells (Agilent Technology, Santa Clara, CA). Colonies were
grown on a 100 ug/mL Kanamycin plates overnight at 35 ̊ C. The following day, a single colony
was chosen and amplified further in XL10-Gold ultracompetent cells using 400mL of LB broth
with 100 ug/mL Kanamycin. After incubation overnight in a shaking incubator at 37 ̊ C, Ad5ffCXCL12 was extracted using a maxiprep kit (Bio-Rad, Hercules, CA). The resulting DNA was
then purified using phenol and 70% ethanol precipitation overnight at -80 ̊ C. The next day the
precipitated DNA was ultracentrifuged at 13,000 rpm for 30 minutes at 4 ̊ C. The resulting
plasmid stock was resuspended in diH2O and analyzed for concentration via nanodrop
(NanoDrop 8000, ThermoFisher, Waltham, MA). The plasmid was confirmed to contain the E1a,
pIX-RFP, CXCL12, and fiber-fibritin genes via PCR.
To prepare the viral plasmid for transfection into the mammalian virus packaging cell
line, HEK293-CXCR4, restriction enzyme digestion using Pac I (New England BioLabs,
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Ipswich, MA) was used to linearize the plasmid. Following digestion, the plasmid was confirmed
via gel-electrophoresis to confirm the presence of a small ligated portion of the viral plasmid,
which confirms the linearization. The resulting linearized DNA was purified and concentrated
via ethanol precipitation at -20 ̊ C. Prepared viral DNA was then transfected (Lipofectamine
3000, Invitrogen, Waltham, MA) into HEK293-CXCR4 cells and incubated at 37 ̊C for 7-14
days. Viral plasmid transfection was monitored for increasing fluorescence over the course of
two weeks, after which potential virus was extracted in PBS from the cells via 3 freeze and thaw
cycles using a dry ice bath. The resulting supernatant was then applied to a fresh dish of
HEK293-CXCR4 cells at 60% confluency for viral rescue. Successful viral rescue was
monitored via fluorescence microscopy until cells exhibited extensive cytopathic effect and
began to detach from the dish surface. Virus extraction was conducted via freeze/thaw cycles,
and fresh HEK293-CXCR4 cells were infected for amplification. The virus was amplified to a
maximum of 60 150mm dishes before harvesting for purification. The resulting virus supernatant
(Ad5-ffCXCL12) was purified on a CsCl2 gradient after which a titer was conducted via AdenoX
Rapid Titer Kit (Clontech, Mountain View, CA). The control virus, Ad5-pIX-RFP-WT/Fiber
(Ad5-WT), was amplified in HEK293 cells and purified via CsCl2 gradient, after which titer was
determined in the same manner as Ad5-ffCXCL12.
3.2.2. Transfections
Viral plasmid and cell line transfections were done via Lipofectamine 3000 (Invitrogen,
Waltham, MA). 293A-CXCR4 and CHO1-CXCR4 cell lines were established through
transfection with a tGFP-CXCR4 expressing plasmid (OriGene Technologies, Rockville, MD).
CHO1-CXCR7 was transfected with a tGFP-CXCR7 expressing plasmid (OriGene
Technologies). Transfected cells were incubated with transfection medium for four hours at 37 ̊
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C, after which, the media was exchanged with fresh media. Transfections were observed within
48-72 hours post-transfection.
3.2.3. PCR
The designated primers were used to test the viral clone and resulting viral DNA, postproduction, for the presence of essential genes (Table 3.1) (Invitrogen, Waltham, MA).
Polymerase-chain reactions (PCR) were performed for 36 cycles at 94◦C for 1 minute, 56◦C for
30 seconds, and 72◦C for 2 minutes. For real-time qPCR, TaqMan Universal Master Mix II
(Applied Biosystems, Foster City, CA, USA) with custom primers and probe (Table 3.2)
(Applied Biosystems) were used to determine AdE4 copy number.
Table 3.1. Primers sets for PCR

Abbreviations: PCR, polymerase chain reaction; RFP, red fluorescent protein
Table 3.2. Primer and probe sequences for qPCR

Abbreviation: qPCR, quantitative polymerase chain reaction
3.2.4. Immunoassays
ELISA. Serial dilutions of Ad5-WT and Ad5-ffCXCL12 were examined for the presence
of SDF-1 and binding, with an ELISA assay (ThermoFisher).
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Western blot analysis. 1.2x106 cells per sample were collected and harvested. Whole
cell lysates were analyzed for expression of CXADR, CXCR4, and CXCR7 using specific
antibodies PA5-31175, 35-8800, PA5-28739, respectively (Thermo Fisher Scientific).
3.2.5. Flow cytometry
Cell receptor analysis. 5x105 cells were harvested with Versene and washed twice with
cold PBS. Cells were incubated at 4◦C for 30 min – 1 hour with anti-mouse IgG, anti-CXCR4,
anti-CXCR7, anti-rabbit IgG (R&D Biosystems, Minneapolis, MN) and anti-CXADR (Sino
Biological Inc, Chesterbrook, PA) antibody in cold PBS. After incubation, cells were washed
twice in cold PBS, then resuspended in 0.5 mL cold PBS and placed on ice. Analysis of receptor
expression was conducted via flow cytometry with a FACSCalibur flow cytometer (BD
Biosciences).
Infectivity assay. Cells were seeded overnight in a 24-well plate at 1x105 cells/well. The
next day, cells were infected with 2% FBS DMEM media with the virus at an increasing
multiplicity of infection [MOI: 1, 10, 50, 100, 500, 1000]. After incubation for 4 hours at 37◦C,
virus-containing media was replaced with complete growth media and incubated at 37◦ C for 48
hours. At 48 hours, cells were harvested, washed three times with PBS, resuspended in 0.5 mL
PBS, and analyzed by flow cytometry.
3.2.6. Cell viability assay
Cells were plated at 1x104 cells per well in a 96-well plate. Cells were infected with the
virus in 100uL 2% FBS DMEM media. Infected cells were incubated at 37 ̊ C for 72-96 hours.
Cell viability post-infection was measured by the XTT assay (9095S, Cell Signaling, Danvers,
MA) at 72 and 96 hours. Absorbance was read at 450 nm, using a plate reader (Molecular
Devices, Sunnyvale, CA, USA).
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3.2.7. siRNA knockdown
CHO1-CXCR4 and CHO1-CXCR7, and the breast cancer MCF-7 cells were treated with
45nM CXADR, CXCR4 and CXCR7 siRNA (Dharmacon, Lafayette, CO, USA). Cells were
incubated 37 ̊ C for 72 hours in transfection media. At 72 hours, the cells were either analyzed by
flow cytometry (with or without antibody) or treated with the virus at 4 ̊ C for 30 min. Virus
treated cells were harvested for DNA extraction.
3.2.8. Statistics
Data are presenting as mean ± standard error or the mean. All data were analyzed with
Student’s t-test using GraphPad Prism 5.0 (GraphPad Software; La Jolla, CA, USA).
3.3. Results
3.3.1. Ad5-ffCXCL12 characterization
After the shuttle and backbone plasmids were transduced into electrocompetent E. coli
cells, the smallest colonies were selected for miniprep plasmid extraction. The plasmid DNA was
digested with the restriction enzyme HindIII, which results in a 6-band ladder when the
adenovirus genomes have been successfully recombined (Figure 3.1A). After recombinant clone
selection, PCR was performed to identify key adenovirus genes, E1A, pIX, Ad-E4, and Ad5penton (Figure 3.1B). We identified clone 7 as a positive recombinant clone containing the
screened genes. Clone 7 DNA was transduced into ultracompetent E. coli cells and amplified.
After amplification, plasmid DNA was extracted, and PCR confirmed the presence of the
modified fiber and CXCL12 insertion (Figure 3.2A). Prior to transfection into the mammalian
cell line HEK293/F28, the viral clone was linearized via restriction enzyme digestion with Pac I
to release the viral DNA. Prior to amplification of the Ad5-ffCXCL12, we established a
HEK293A-CXCR4 adenovirus packaging cell line that overexpresses human CXCR4 (Figure
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A.

B.

Figure 3.1. Recombinant clone confirmation (A) Potential recombinant clone digested with
restriction enzyme HindIII. All clones exhibited a ladder. Clones 5, 6, and 7 were selected for
screening. (B) Potential recombinant clones 5, 6, and 7 screened for adenovirus genes E1A, pIX,
Ad-E4, and Ad5-penton. Clone 7 was confirmed positive for the selected genes.
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3.2B and C). This new cell line allowed for efficient replication and amplification of Ad5ffCXCL12. After production and purification of the viral stocks for Ad5-WT and Ad5-ffCXCL12,
PCR on Ad5-ffCXCL12 viral stock confirmed the presence of the T4 fiber-fibritin and CXCL12
genes (Figure 3.3A). An ELISA for CXCL12 protein confirmed the presence of the CXCL12
ligand on the virus capsid (Figure 3.3B).

A.

B.

C.

D.

Figure 3.2. Ad5-ffCXCL12 recombinant clone confirmation. (A) PCR confirmation of
recombinant plasmid. The recombinant clone is positive for both shuttle and backbone genes. (B)
The packaging cell line HEK293A (purple peak) and HEK293A-CXCR4 (pink peak) in flow for
detection of CXCR4-GFP after sorting for CXCR4 enrichment. (C) Fluorescence microscopy of
HEK-293-CXCR4 overexpressing human CXCR4 tagged with GFP. (D) The HEK-293-CXCR4
(figure cont’d.)
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cell line shows high levels of infection observable via RFP that is tagged onto the viral capsid.
Abbreviations: RFP, red fluorescent protein; PCR, polymerase chain reaction; GFP, green
fluorescent protein
A.

B.

C.

Figure 3.3. Ad5-ffCXCL12 virus confirmation. (A) PCR confirmation of final virus stock after
amplification in 293A-CXCR4 cell line and purification with CsCl gradient. (B) ELISA
confirmation of CXCL12 protein presence in purified viral stock. (C) Schematic of Ad5ffCXCL12 genome. Error bars are representative of ± SEM. Abbreviations: VP, viral particles;
PCR, polymerase chain reaction; CsCl, cesium chloride; SEM, standard error of the mean
3.3.2. Breast cancer cell lines express varying levels of CXCR4, CXCR7, and CXADR
A panel of breast cancer cells lines and the immortalized breast epithelial cell line, MCF12A, were analyzed via flow cytometry for receptor expression. These results indicate that the
cell lines contain subpopulations expressing CXCR7 and CXADR at varying levels at the cell
surface (Figure 3.4). CXCR4 was not detected via flow cytometry. Western Blot analysis of
whole cell lysate, however, detected varying levels of CXCR4 (Figure 3.5). The discrepancy
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between the two methods of receptor identification may be due to endocytosis of the receptors
upon antibody binding for flow cytometry, or to the presence of intracellular CXCR4. CXCR7
was found in all cell lines as distinct populations of cells during flow cytometry, except in MDAMB-436 (TNBC/basal), where the cells express a homogenous mixture (Figure 3.4). Western
blot confirmed CXCR7 presence, as well, in most cell lines, with the highest expression seen in
BT-20.

Figure 3.4. Cellular receptor expression. Flow cytometry on the breast cell panel incubated with
antibodies staining for cell surface CXCR4, CXCR7, and CXADR (hCAR). Unstained cells
(green peaks) were compared to isotype IgG staining (purple peaks) and antibody staining (pink
peaks). We did find that the immortalized epithelial cell line, MCF-12A exhibits low levels of
CXCR7 at the cell surface. All other cell lines are breast cancer cells with varying levels of
CXCR7 and CXADR at the cell surface.
Similarly, the Ad5 endogenous receptor, CXADR, was present at varying levels in all cell
lines with cell lines MCF-12A, MCF7 (luminal A), MDA-MB-231 (TNBC/basal), and MDAMB-436 (TNBC/basal) expressing high levels. Western blot analysis of CXADR found similar
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levels of the receptor in most cell lines, with the highest expression visible in MDA-MB-436
(Figure 3.5). It is worth mentioning that the differences in expression levels between the two
detection methods may lie in receptor locations within the cell or cell membranes.

Figure 3.5. Western blot (non-quantitative) of breast cell panel detects the CXCR4 receptor in all
cell lines, contrary to flow cytometry, which indicated a lack of the receptor at the cell surface.
Breast cell line BT-20 shows high levels of CXCR7, while MDA-MB-231 and MDA-MB-436
show higher levels of CXADR, as supported by flow cytometry analysis of cell surface receptors
(Figure 3.3).
3.3.3. Ad5-ffCXCL12 efficiently targets and enhances infection efficacy in breast cancer
cells
Cells were infected at increasing MOI with either Ad5-WT or Ad5-ffCXCL12. All breast
cancer cell lines had a significantly greater infection with Ad5-ffCXCL12 compared to Ad5-WT
(Figure 3.6 and 3.7) starting at 10 or 50 MOI. Ad5-ffCXCL12 significantly enhanced infection
when compared to Ad5-WT, even in the presence of high levels of CXADR, as was seen in
MDA-MB-231 and MDA-MB-436 (Figure 3.4). We also identified high levels of CXADR in
MCF-7 cells; however, Ad5-WT infection was largely inhibited, suggesting that productive
infection with Ad5-WT is perhaps mediated by additional cellular proteins (Figure 3.6). Infection
of MDA-MB-231 (low CXCR4 and CXCR7) with Ad5-ffCXCL12 did not have similar decreases
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in infection efficiency, suggesting that the receptors mediate uptake of the modified virus
regardless of expression level. The overall infection however, of the non-tumorigenic breast
epithelial cell line, MCF-12A (moderate internal CXCR4, low membrane CXCR7, high
membrane CXADR), with Ad5-ffCXCL12 was attenuated when compared to the breast cancer
cell lines. Of note, even in the presence of high levels of CXADR, infection with Ad5-WT did not
correlate with the high CXADR expression suggesting that infection was not necessarily
dependent on the level of receptors. The increase of infection however, in MCF-12A with Ad5ffCXCL12 may be mediated by additional cellular factors, such as alpha and beta integrins.

Figure 3.6. Flow cytometry of Ad5-WT or Ad5-ffCXCL12 breast cell infection at increasing MOI.
Flow cytometry experiments were conducted 48 hours post-infection. All data is representative
of three replicate experiments. Error bars indicate the ± SEM. **p < .01, ***p < .001 using
Student’s t-test for comparison of viruses. Abbreviation: MOI, multiplicity of infection
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Figure 3.7. Fluorescence microscopy of Ad5-WT or Ad5-ffCXCL12 breast cancer cell infections
at increasing MOI. Photos are 48 hours post-infection. Scale bar represents .25 mm.
Abbreviation: MOI, multiplicity of infection
3.3.4. Ad5-WT and Ad5-ffCXCL12 exhibit similar oncolysis
Cell viability after the infection was assessed at increasing MOI of either virus. Here, two
cell lines, MCF-12A and MDA-MB-436, were compared at 72 and 96 hours post-infection. Both
cell lines expressed variable levels of CXCR7 and CXADR (Figure 3.4). We show that cell
viability of cells infected with Ad5-ffCXCL12 was comparable to viability after Ad5-WT
infection (Figure 3.8), suggesting that oncolytic efficiency is similar between the two viruses and
thus the incorporation of the ff-CXCL12 does not hinder oncolytic efficiency. Overall, a
decrease of cell viability at MOI 100 and 1000 was statistically significant (p < .001) compared
to that of uninfected cells. MCF-12A exhibits slower decreases in cell survival between 72 and
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96 hours; however, MDA-MB-436 cells seemed more susceptible to both viruses at higher doses
when compared to MCF-12A. Growth inhibition of cells, however, at these MOIs could be
attributed to direct oncolysis, or the cytotoxic and bystander effects of either virus, at those
concentrations.

A.

C.

B.

D.

Figure 3.8. XTT assays of Ad5-WT or Ad5-ffCXCL12 infections in MCF-12A and MDA-MB-436
with increasing MOI. Significant reduction in cell viability was seen at 100 and 1000 MOI over
the course of 96 hours. (A-B) MCF-12A at 48 and 96 hours post-infection. (C-D) MDA-MB-436
at 48 and 96 hours post-infection. All data is representative of five replicates normalized to
uninfected cells (100% cell viability). Error bars indicate the ± SEM. ***p < .001 using
Student’s t-test. Abbreviations: MOI, multiplicity of infection; SEM, standard error of the mean.
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3.3.5. Isogenic cell line CXCR7 and CXCR4 specific infection with Ad5-ffCXCL12
Chinese hamster ovary cells were used as an isogenic cell differing only in the expression
of human receptors CXADR, CXCR4 and CXCR7. Expression of CXCR4 and CXCR7 was
assessed by flow cytometry utilizing a tGFP reporter gene fused to the receptor sequences
(Figure 3.9). Further flow analysis was conducted using antibody targeting CXCR4 and CXCR7
(Figure 3.9). Of note, tGFP reporter expression was more highly expressed in comparison to
cells incubated with anti-CXCR4 or anti-CXCR7. This discrepancy could be attributed to
localization of the receptors at different levels in cellular compartments.

Figure 3.9. CHO1- CXCR4 and CHO1-CXCR7 receptor expression analysis via flow cytometry
after transduction of human GFP-tagged receptors. GFP (left column, designated by green peak)
indicates higher expression of the receptors while antibody staining at the cell surface (pink
peaks in right column) detects smaller amounts. Abbreviations: GFP, green fluorescent protein;
RFP, red fluorescent protein.
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As expected, CHO1 parental cells were refractory to Ad5-WT (Figures 3.10A and 3.11),
but were inherently susceptible to Ad5-ffCXCL12 infection (Figure 3.11), with a statistically
significant infection at 500 and 1000 MOI when compared to Ad5-WT. This modest increase in
infected cells may be attributed to hamster protein interactions with our modified fiber and knob,
as Ad5-WT was not able to infect CHO1. Expression of human CXADR (CHO1-hCAR) was
accompanied by an expected increased infection with Ad5-WT (Figures 3.10B and 3.11). CHO1hCAR was also unexpectedly susceptible to Ad5-ffCXCL12 infection (Figures 3.10C, D, and
3.11). In comparison, CHO1-CXCR4 and CHO1-CXCR7 infections were facilitated by Ad5ffCXCL12 alone. Infection in both cell lines was lower than expected with Ad5-ffCXCL12,
possibly attributable to the accelerated cell growth of uninfected cells that we observed when
compared to human breast cancer cell lines.
3.3.6. siRNA knockdown of CXCR4 and CXCR7 diminishes Ad5-ffCXCL12 binding
CHO1-CXCR4 and CHO1-CXCR7 cells were treated with anti-CXCR4 and anti-CXCR7
siRNA, respectively. Figure 3.12 shows the CHO1-CXCR4 siRNA treated cells 72 hours post
treatment. Even with high amounts of siRNA (45 nM), knockdown was not complete based on
GFP expression. For cells treated with virus, cells were infected with 100 MOI of either Ad5-WT
or Ad5-ffCXCL12 for 30 minutes. After infection, DNA was harvested for qPCR and Ad-E4 copy
number was used to detect the amount of virus bound. After siRNA treatment, viral binding via
Ad5-ffCXCL12 was decreased in CHO1-CXCR4 by 45% and 43% in CHO1-CXCR7 (Figure
3.13A). The same experiment was conducted with MCF-7 breast cancer cells. Treatment with
hCAR siRNA resulted in a decrease of 25% in Ad5-WT binding and a 37% decrease in Ad5ffCXCL12 binding in MCF-7 breast cancer cells (Figure 3.13B). Ad5-ffCXCL12 binding was not
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Figure 3.10. Fluorescence microscopy 48 hours after infection with Ad5-WT or Ad5-ffCXCL12 in
CHO1 cell lines. Scale bar represents .25 mm. Visible RFP indicates virus replication and
infection of cells. Numbers indicate MOI. (A) CHO1 parental cells. (B) CHO1-hCAR (CXADR)
cells. (C) CHO1-CXCR4 (D) CHO1-CXCR7. Abbreviation: RFP, red fluorescent protein.
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inhibited in MCF-7 cells treated with CXCR4 siRNA. A 15% decrease, however, was seen in
MCF-7 cells treated with CXCR7 siRNA.

Figure 3.11. All CHO1 cell lines (-receptors, +CXADR, +CXCR4, + CXCR7) were infected
with increasing MOI of either Ad5-WT or Ad5-ffCXCL12. All data is representative of three
replicate experiments. Error bars indicate the ± SEM. *p < .05, **p < .01, ***p < .001 using
Student’s t-test comparing viruses. Abbreviation: MOI, multiplicity of infection.
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Figure 3.12. Representative figure of siRNA knockdown with 45nM of anti-CXCR4 siRNA after
72 hours. Y-axis is representative of GFP, and x-axis is RFP. Here only GFP is observed as
antibody incubation was not accurate in detecting surface receptor (data not shown).
Abbreviation: siRNA, silencing RNA.
3.4. Discussion
In this study, we evaluated the efficacy of incorporating the CXCL12 ligand into the
knob domain of a modified Ad5 fiber-T4-fibritin shaft. Previously our lab has demonstrated the
efficacy of retargeting a replication-deficient adenovirus to CXCR4 and CXCR7 using a bispecific adaptor molecule.35 The replication deficient Ad5 was successfully retargeted to cancer
cells overexpressing CXCR4 and successfully detargeted the liver in vivo. However, due to the
unknown safety and pharmacokinetics of the bi-specific adaptor and virus complex, the present
study sought to incorporate the CXCL12 ligand directly into the adenovirus genome. We have
demonstrated successful incorporation of the CXCL12 gene via PCR and have performed a
binding assay using a CXCL12 ELISA to identify CXCL12 protein in our viral stock (Figure
3.2).
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A.

B.

Figure 3.13. qPCR post siRNA treatment and infection of (A) CHO1-CXCR4, CHO1-CXCR7
and (B) MCF-7. Infections were conducted at 100 MOI for 30 minutes at 4 ̊ C. Post-infection cell
pellets were washed with cold PBS and DNA harvested. 25ng qPCR reactions were used for all
conditions. Black bars represent Ad5-WT infected samples and gray bars represent Ad5ffCXCL12 infected samples. All data is representative of three replicate experiments. Error bars
(figure cont’d.)
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indicate the ± SEM. siRNA treatments were normalized to DharmaFect infection (representing
100% infection). ***p < .001 using Student’s t-test comparing siRNA treated conditions to
control infections using DharmaFect. Abbreviations: siRNA, silencing RNA; qPCR, quantitative
polymerase chain reaction; MOI, multiplicity of infection; SEM, standard error of the mean.
The CXCR4-CXCR7-CXCL12 axis has been implicated in the initiation, progression and
metastasis of cancer cells. For over two decades, CXCL12 has been known as a specific ligand to
the chemokine receptor, CXCR4.24 In 2005, CXCR7 was discovered to also have high binding
affinity to CXCL12.33 Since then, the involvement of the CXCR4-CXCR7-CXCL12 axis in
breast cancer has been extensively explored. CXCR4 has shown to be expressed in a variety of
cancers, including breast cancer.37 Specifically, CXCR4 has been implicated in tumor cell
survival and progression, epithelial-mesenchymal transition (EMT), trafficking of cancer cells,22
and metastasis.22,26,27
CXCR7 also is overexpressed in a variety of cancers, including breast cancer.34 It has
been primarily considered a scavenger receptor for CXCL12, with the purpose of managing
extracellular CXCL12 levels and limiting CXCL12-CXCR4 binding.38,39 It has also been
implicated in progression and metastasis of CXCR4-expressing tumor cells.39,40 In contrast,
CXCR7 expression in breast cancer tumor vasculature has been shown to control and inhibit
metastasis.31 Despite the common consensus that CXCR7 acts as a sequestering receptor for
CXCL12, recent evidence has shown that CXCL12-CXCR7 binding results in downstream
signaling affecting cancer stem cell (CSC) survival and proliferation, as well as EMT41,42 and
metastasis.34
The therapeutic importance of targeting the CXCR4-CXCR7-CXCL12 axis in breast
cancer has been widely recognized, in part due to overexpression of both receptors occurring at
variable levels in different stages and subtypes of breast cancer.43-47 The present study sought to
utilize this chemokine axis to retarget an oncolytic Ad5 to increase infection in breast cancer
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cells. The wild-type receptor for Ad5, CXADR, is typically downregulated in breast cancer
tumor cells, thus limiting therapeutic efficacy of wild-type fibered Ad5 vectors.17 The utility of
retargeting Ad5 with fiber modifications has been shown to be a viable therapeutic approach.1115,19-21

Specifically, the replacement of the Ad5 fiber-knob with T4-fibritin maintains the

structural integrity of the Ad5 fiber and allows for larger ligand insertions into the knob
domain.48,49 Previously, our laboratory utilized the T4-fibritin platform to successfully retarget
an oncolytic adenovirus to the cMet receptor in hepatocellular carcinoma and breast cancer.50
CXCR4 and CXCR7 have been found to be expressed either in separate populations of
cells or co-expressed on the same cells within breast tumors.30,34,47,51 In addition to coexpression, both receptors have been observed to heterodimerize to induce signaling.32,52,53 In our
study, receptor expression analysis found variable levels of CXCR7 and CXADR receptors at the
cell surface (Figure 3.4) in addition to the presence of CXCR4 in whole cell lysate (Figure 3.5).
While we were unable to find expression of CXCR4 at the cell surface by flow cytometry,
western blot identified the presence of CXCR4 in all cell lines, including MCF-12A. This
discrepancy may be attributed to the presence of internally localized CXCR4. Subcellular
localization of CXCR4 has been shown in hepatocarcinoma cells to be independent of cell
surface localization of CXCR454 and may contribute to the expression differences we see
between the two methods. In this study, CXCR7 expression was seen primarily in
subpopulations of breast cancer cell lines and MCF-12A. Western blot identified CXCR7 in most
of these cell lines with the lowest expression in MDA-MB-231 and MCF-12A cells (Figures 3.4
and 3.5), which has also been previously reported.40,55
Infection efficiency was analyzed via flow cytometry after a 48-hour infection at
increasing MOI of Ad5-WT or Ad5-ffCXCL12. As expected, Ad5-ffCXCL12 exhibited greater

79

infection in breast cancer cells when compared to Ad5-WT. Breast cancer cell lines MDA-MB231 and MDA-MB-436 exhibited high levels of CXADR (Figure 3.4 and 3.5), and thus, Ad5-WT
infection was greater in these cell lines when compared to others (Figure 3.6 and 3.7). High
levels of CXADR, however, are not sufficient to guarantee infectivity. MCF-12A has high levels
of CXADR, yet this cell line was not efficiently infected with Ad5-WT (Figure 3.6), suggesting
that WT infection may be further mediated by additional cellular components. In contrast, Ad5ffCXCL12 infection was increased, likely due to the presence of CXCR7 (Figure 3.4) at the cell
surface. Overall MCF-12A infection, however, with Ad5-ffCXCL12 was attenuated when
compared with breast cancer cell lines (Figure 3.6), possibly attributable to low levels of ανβ3
and ανβ5 at the cell surface.35
In modifying proteins on the Ad5 capsid, there is a risk of destabilization of the virus;
thus, the virus may not be able to infect and replicate within the cells effectively. Previously, the
T4 fiber-fibritin insertion into the Ad5 genome was demonstrated to maintain viral stability.48
While the infection experiments that we carried out clearly demonstrate the virus is capable of
replicating in breast cancer cells, we also assessed cell viability after infection in the human nontumorigenic breast epithelial cell line MCF-12A and human breast cancer cell line MDA-MB436. We found that MDA-MB-436 cells were similarly vulnerable to infection with both viruses,
suggesting that infection with Ad5-ffCXCL12 can lyse or inhibit cancer cell growth similarly to
Ad5-WT (Figure 3.8). Also, MCF-12A infection with Ad5-ffCXCL12 resulted in a decrease in
cell survival at higher MOIs at 96 hours post-infection, likely attributable to the presence of
CXCR7 detected in this cell line.
In this present study, Chinese hamster ovary (CHO1) cells were used as an isogenic cell
line to determine single receptor interactions (Figures 3.10 and 3.11). We found that CHO1 cells
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were not infected by Ad5-WT yet can interact at low levels with Ad5-ffCXCL12. As expected,
with overexpression of CXADR, Ad5-WT infection was increased. With overexpression of
CXADR, Ad5-ffCXCL12 infection also increased, suggesting that CHO1-CXADR cells can
interact with our modified fiber or at the very least still interacts with the N-terminus of the WT
Ad5 fiber portion still present in the modified fiber. Similar results have been previously
reported for CHO1 cells, where the modified fiber adenovirus was able to interact with parental
CHO1 and exhibited similar increases in infection with CHO1-hCAR (CXADR) cells.12 These
results suggest that the fiber modification may have interactions with CHO1 intrinsic proteins. In
CHO1-CXCR4 and CHO1-CXCR7 we observed small increases in infection with Ad5-ffCXCL12
over Ad5-WT (Figure 3.11). These small increases may be associated with lower levels of the
receptor expression throughout the CHO1 population, as these populations were not receptor
enriched. In addition, CHO1-CXCR4 and CHO1-CXCR7 cell growth were observed to duplicate
three to four times within a 24-hour period, perhaps contributing to uninfected cells outgrowing
infected cells within the 48-hour infection period.
Ad5 binding is typically mediated by the CXADR receptor and alpha-v-beta integrins. In
the absence of CXADR however, Ad5 binding has been shown to be mediated by a host of cell
surface receptors. Heparan sulfate glycosaminoglycans have been found to act as fiberindependent and fiber-dependent binding receptors for Ad5.56,57 The alpha-v-beta-5 integrin, one
of the Ad5 co-receptors that binds to the penton base, has also been shown to act as a primary
receptor in the absence of CXADR.58 That study demonstrated that the binding of alpha-v-beta-5
to Ad5 remained fiber-independent as binding occurred at the penton base.58 While this
interaction was to be expected, the surprise was that the binding of penton and alpha-v-beta-5
facilitated infection independently from CXADR in MCF-7 cells.58 This result explains the slight
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decrease in binding in our MCF-7 cells treated with siRNA (Figure 3.13B); the presence of
surface alpha-v-beta-5 may have contributed to the binding of Ad-ffCXCL12 and thus prohibited
a larger decrease in virus binding. The CHO-CXCR4 and CHO1-CXCR7 cells exhibited a
marked decrease in binding that is explainable by the siRNA treatment, even while it was not a
complete knockdown as shown by Figure 3.12.
The isogenic cell lines (CHO1) were able to show that our modified virus was specific to
CXCR4 and CXCR7 as binding was affected through the siRNA treatments. It is, however,
important to note, that due to the lack of complete receptor abolishment (data not shown), a
larger decrease in Ad5-ffCXCL12 binding may have been prevented. Also, in our breast cancer
cell line (MCF-7), a smaller decrease in binding may have been in part through incomplete
knockdown or through the presence of other receptors and proteins known to bind Ad5. Since the
experiment was conducted at 4̊ C, the resulting virus copy number would be virus bound to the
cell surface and not representative of internalization. In MCF-7, due to the potential interactions
between alpha and beta integrins58 and heparan sulfate glycosaminoglycans,56 the binding of
Ad5-ffCXCL12 and Ad5-WT may not have been effectively inhibited at the cell surface.
Therefore, the decrease in binding we show may not be representative of the total decrease in
internalization that may occur under physiological conditions.
3.5. Conclusion
In conclusion, this study showed an increased infection efficiency of a fiber-modified
adenovirus (Ad5-ffCXCL12) in breast cancer cells primarily overexpressing CXCR7 and in
HEK293 cells overexpressing CXCR4. In addition, Ad5-ffCXCL12 oncolytic efficiency was
similar to that of the Ad5-WT control, suggesting that the modifications did not impair the virus’
ability to replicate within the cell. We were able to demonstrate a degree of specificity to the
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CXCR4 and CXCR7 receptors in an isogenic hamster cell line. The major limitations we
observed in controlling infection in breast cancer cells, however, are likely due to additional
proteins on the cell’s surface that mediate viral infection, independent of the fiber. Further
studies need to assess the ability to simultaneously target the adenovirus to a specific receptor
and block binding of hexon to extracellular receptors, such as heparan sulfate
glycosaminoglycans.
In addition, this virus will need to be assessed in a replication-permissive
immunocompetent animal model to characterize its oncolytic ability in an in vivo setting
adequately. Currently, there is no animal model available for assessing adenovirus infection in an
immunocompetent system with breast cancer. The most common animal models to be utilized in
preclinical oncolytic adenovirus studies have been murine xenograft models. Unfortunately,
since immunocompetent murine models are not permissive to Ad5 infection due to serotype
specificity, accurate assessment of Ad5 vectors preclinically has been sorely limited. Thus far,
Syrian hamster and porcine models have emerged as replication-supportive animal models for
Ad5.59-61 In order to utilize either model, a suitable breast cancer cell line overexpressing
CXCR4 and/or CXCR7 must be developed. Overall, we have developed a strong therapeutic
oncolytic adenovirus candidate for breast cancer therapy that warrants further investigation.
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CHAPTER IV. CONCLUSION, LIMITATIONS AND FUTURE DIRECTIONS FOR
ONCOLYTIC ADENOVIRUSES IN BREAST CANCER
4.1 Introduction
Localized breast cancer is easily treated with resulting high five-year survival rates;
however, more advanced cases pose a challenge to current treatments. Unfortunately, about 73%
of women who are diagnosed with advanced stage breast cancer are unlikely to survive past five
years after diagnosis, even with treatment.1 One of the major problems in this cohort is that the
treatments available with systemic administration have difficulty targeting distant metastasis,
particularly due to the toxicity of conventional treatments2. To further compound the difficulty in
treating systemically, recurrent breast cancers are typically resistant to the previous treatments.2
As a result, recurrent, resistant and metastatic breast cancer cases are very aggressive and do not
respond well to conventional treatments such as radiation and chemotherapy. In addition, since
the course of treatment for localized breast cancer is often based on characterizing tumors, these
often rely on biopsies to determine the course of action and in the case of metastatic breast
cancer, tumors are inaccessible. Thus, new targeted treatments that (a) are not limited by
hormone receptor status; (b) are capable of systemic administration; and (c) can induce oncolysis
in tumor cells while sparing normal tissue, are ideal candidates as treatments for advanced stage
breast cancer.
Oncolytic viruses are good candidates for use in breast cancer treatment. They can be
engineered to (1) specifically target cancer cells, (2) express therapeutic transgenes, (3) act as
immunotherapeutic agents, and (4) decrease the toxicity associated with conventional treatments.
The ideal oncolytic viral vector would be administered systemically and have the following
characteristics: (1) targets only cancer cells, (2) has restricted replication to cancer cells, (3) has
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therapeutic transgene expression, (4) exhibits robust intratumor oncolytic activity, and (5) has a
low or synergistic effect with the immune system.
While there are many oncolytic viruses in development, only T-VEC has reached clinical
approval in the United States.3-5 Adenovirus, however, is the most extensively studied and tested
virus preclinically and clinically and has progressed significantly in the last decade. Clinical
approval, however, remains elusive, due to decreased efficacy in clinical trials when compared to
pre-clinical results. This decreased efficacy can be attributed to a range of systemic and
intratumor barriers. Breast cancer is a solid tumor, and within solid tumors, the stoma
components make up the majority of the tumor volume when compared to cancer cell number.
This stroma can affect adenovirus spread by trapping virus in dense extracellular matrix,
inhibiting spread through the high pressure of the tumor environment, downregulation of E1A
activity under within hypoxic conditions, and finally, the presence of immune cells that can
activate an antiviral response.6,7 Likewise, adenovirus injected systemically is susceptible to
rapid clearance from the blood through neutralizing antibodies and virus binding with
coagulation Factor X.8,9
Previously, our lab has successfully used a bispecific adaptor to redirect a replicationincompetent wild-type fibered adenovirus to CXCR4 and CXCR7, in breast cancer.10 In the
present study we focused on genetically redirecting a replication-competent adenovirus to breast
cancer cells overexpressing the chemokine receptors CXCR4 and CXCR7. We sought to
determine whether modification of the fiber and knob domain to express the CXCL12 ligand
would allow for increased infection efficiency into breast cancer cells when compared to wildtype fibered virus. We conclude that our virus, (1) had increased infection efficiency of breast
cancer cells overexpressing CXCR7, (2) targeted cells that specifically overexpress CXCR4
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(293-CXCR4 and CHO1-CXCR4), and (3) has similar oncolytic efficacy as the control (Ad5WT).
This study has set the foundation for future assessments in vivo for specificity and tumor
oncolysis within an immunocompetent animal model, such as the Syrian hamster or porcine
models. It will be imperative to understand the immune interactions with our virus in an
adenovirus-permissive animal model, in order to determine the necessary adjustments for
efficient tumor transduction. In addition, the present study provides proof-of-concept data for
further modifications to the vector. To date, oncolytic adenoviruses for breast cancer have been
engineered if multiple ways to overcome barriers and increase therapeutic efficiency (Figure
4.1A). This study took a similar engineering approach with the goal to increase therapeutic
efficacy through more efficient targeting of cancer cells (Figure 4.1B). Since the early 2000s,
the sodium/iodide symporter (NIS) gene has been utilized in oncolytic viruses to monitor
oncolytic virus activity noninvasively, with radioactive iodine (131I).11 In addition to imaging
capabilities, the NIS gene can provide therapeutic benefits through synergistic therapy via viral
oncolysis and radiotherapy. In the future, we plan to incorporate a sodium/iodide symporter
(NIS) gene under control of the E1A promoter that will result in transgene expression during the
viral life cycle, thus allowing for viral monitoring and combination therapy.
4.2 Limitations
In this study, a few experiments resulted in less than conclusive results; for example, the
XTT and the siRNA binding assays were chosen to determine oncolytic effects and specificity of
Ad5-ffCXCL12 when compared to Ad5-WT. For the XTT assay, only 72 and 96 hour time-points
were assessed based on the observation of cell death at 48 hours seen in the infectivity assays. In
retrospect, the XTT assay could be observed at later points, for example over the course of 10
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A.

B.

Figure 4.1. Oncolytic adenovirus genome. (A) Schematic of modifications to oncolytic
adenovirus vectors within the literature. (B) Schematic of Ad5-ffCXCL12. Abbreviations: ITR,
inverted tandem repeat; bp, base pair; RFP, red fluorescent protein; ff, fiber fibritin.
days post-infection.12-15 This would reduce the possibility of decreased cell survival due to
cytotoxicity from exposure to the virus, and the lower MOIs would show more accurate results
over a longer duration. The choice in cell lines was based on cancer vs. normal cell death with
exposure to Ad5-ffCXCL12, where it was expected to have greater oncolytic effect in the cancer
cell line (MCF-7) over the control cell (MCF-12A). However, a significant difference in the
oncolytic effect was not observed between the two viruses possible attributed to the
immortalized nature of the control cells or the toxic nature of the viruses at higher MOI. In order
to more accurately assess oncolytic differences in these cells, the lower MOIs should be
observed over the course of 10 days to determine the differences between the cell lines.
The XTT assay is a metabolism-based assay that determines cell viability through
actively respiring cells that convert XTT to formazan, which can be analyzed via
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spectrophotometer. Often metabolic assays such as the XTT are used to indirectly measure
oncolysis through cell viability. Other metabolic assays typically used in the literature include
the MTS,16,17 MTT,18,19 and resazurin20 assays which measure the viable cells remaining. Nonmetabolically reliant assays that can be used are crystal violet21,22 and sulforhodamine B staining
(SRB)23 assays which stain living cells to determine cell viability. Each assay provides an
indirect measure of oncolysis. In this study, these assays would have been appropriate choices to
measure oncolysis, including the choice to use the XTT assay. The major limitation, however,
for this experiment was the length of time that chosen to analyze cell viability. As discussed
earlier, it would be relevant to observe cell viability over a longer course of time.
Due to the inconclusive nature of the XTT assays that were performed, an isogenic cell
line, CHO1 was chosen to assess the specificity of Ad5-ffCXCL12 to the receptors CXADR,
CXCR4 and CXCR7. As expected, the CHO1 cell line was refractory to Ad5-WT infection.
However, Ad5-ffCXCL12 exhibited some infection indicated that perhaps there was intrinsic
interaction between CHO1 proteins and the modified fiber. With the overexpression of CXADR,
the CHO1 cells became susceptible to infection with Ad5-WT and with Ad5-ffCXCL12 to a
higher degree. This result was unexpected despite being seen in the literature, and therefore, it
was difficult to surmise that Ad5-ffCXCL12 was specific for the CXCR4 and CXCR7 receptors.
In an effort to narrow down the specificity, siRNA experiments were performed to downregulate
the receptors in order to observe specificity through binding assays.
In retrospect, since binding of adenovirus can be mediated by various cell surface
proteins, other experiments that take this in consideration could be conducted to prevent binding
of the adenovirus to other cell surface proteins. Preventing (extraneous) protein binding can help
determine the extent of reduced binding of Ad5-ffCXCL12 in the siRNA studies. Integrin
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inhibitors such as echistatin and cilengitide could prevent adenovirus binding to integrins at the
cell surface during exposure to adenovirus. By preventing integrin binding, the efficacy of the
binding experiments performed in this study could be increased.
Of note, binding assays do not conclude the infection efficiency based on receptor
specificity of the virus. To help further elucidate virus specificity, competitive infection assays
could be performed to assess how specific Ad5-ffCXCL12 is for the receptors CXCR4 and
CXCR7. In order to do so, prior to infection, cells would be incubated with competitive
inhibitors or receptor antagonists. This type of experiment would be useful with breast cancer
cells, as alternative receptors can be blocked so that the adenovirus would be unable to use them.
For example, AMD3100 is an antagonist for the CXCR4 receptor and could be utilized to assess
infection through the CXCR7 receptor. Likewise, CCX771 antagonist for CXCR7 could be
utilized to assess CXCR4 specific infection. In addition to these experiments, the binding
experiment in the breast cancer cells, MCF-7 could be improved by inhibiting both integrins and
either CXCR4 and CXCR7 to increase receptor specificity. Additionally, during these
competitive and inhibition assays, all receptors and integrins could be blocked prior to infection
to asses off-target infection. These types of experiments could lead to more conclusive results on
Ad5-ffCXCL12 specificity to the CXCR4 and CXCR7 receptors.
4.3 Conclusion
Oncolytic adenovirus remains a promising candidate for oncolytic virotherapy. While
barriers exist at the preclinical and clinal levels, these are being investigated extensively to
improve therapeutic benefit while maintaining low toxicity. Due to the downregulation of the
adenovirus wild-type receptor, CXADR, alternative routes into cancer cells are being
investigated. Our study attempts to address this issue by targeting commonly overexpressed
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chemokine receptors, CXCR4, and CXCR7. To our knowledge, this study is the first to redirect
an oncolytic adenovirus to the CXCR4/CXCR7 axis in breast cancer. In addition, the present
study demonstrates that infection with our virus, Ad5-ffCXCL12, is superior to Ad5-WT infection
in breast cancer cells in vitro. However, to more accurately assess our hypothesis that we were
able to redirect Ad5-ffCXCL12 to the CXCR4 and CXCR7 receptors, more specific experiments,
as described above, could help further elucidate receptor specificity. In addition, future studies
will determine whether the increased transduction that we observed in vitro is translatable in vivo
and thus lay the foundation for additional modifications to the vector itself.
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